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ABSTRACT
Background: Left ventricular assist devices (LVAD) are operated at constant 
speeds (rpm), consequently, pump flow is passively determined by the pressure 
difference between the LV and aorta. Since the diastolic pressure gradient (~70 mmHg) is 
much larger than the systolic gradient (~10 mmHg), the majority of pump flow occurs 
during systole. This limitation results in sub-optimal LV volume unloading, LV washing, 
and diminished vascular pulsatility that may be associated with increased risk for 
clinically-significant adverse events, including stroke, bleeding, arteriovenous 
malformations, and aortic insufficiency.  To address these clinical adverse events, an 
intelligent control strategy using pump speed modulation was developed to provide 
dynamic LV unloading during the cardiac cycle to produce near-physiologic pulsatile 
flow delivery similar to that of the native heart.   
Materials and Methods: The objective of this study was to integrate a novel 
algorithm to dynamically control Medtronic HVAD pump speed and demonstrate proof-
of-concept by characterizing hemodynamic performance in a mock flow loop primed 
with a blood analog solution (glycerol-saline, 3 cP) and tuned to simulate class IV heart 
failure (HF). The intelligent LVAD control was operated a varying pump speeds (Dspeed 
= 0, 1000, 1500, 2000, 2500 rpm) and systolic durations (30%, 35%, and 40%); systolic 
duration correlates to the time spent at either the high or low pump speed setting. The 
intelligent LVAD control strategy modulates pump speed within a cardiac cycle triggered 
from an R-wave of an EKG waveform set to 80 BPM. This pump speed modulation 
control strategy allows for pulsatile operation of a continuous flow LVAD within a single 
cardiac cycle. Hemodynamic waveforms (LV pressure-volume, aortic pressure-flow, and 
pump flow) and intrinsic pump parameters (speed and current) were recorded and 
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analyzed for each test condition. We hypothesize that pump speed modulation may be 
configured for optimal volume unloading (rest), vascular pulsatility (reloading), and/or 
washing.  
Results and Discussion: The intelligent LVAD control system successfully 
demonstrated the ability to rapidly increase and decrease HVAD pump speed within a 
single cardiac cycle to provide asynchronous, synchronous co-pulsation, and synchronous 
counter-pulsation profiles for all systolic durations (30, 35, 40%) and Drpm tested 
(D1000, D1500, D2000, D2500). Asynchronous support was achieved when pump speed 
increase (or decrease) was independent of the cardiac cycle, co-pulsation support was 
achieved when increase in pump speed was timed with beginning of systole 
corresponding with ventricular contraction (systole), and counter-pulsation support was 
when increase in pump speed was timed with the end of systole corresponding with 
ventricular filling (diastole). Ideally, the intelligent control would increase (or decrease) 
the HVAD pump speed instantaneously upon R-wave detection; however, two distinct 
time delays were observed: (1) a time delay from detection of the R-wave trigger and 
increase (or decrease) of pump speed for systolic durations of 35% and 40% (being 45 ± 
3.0 ms and 82 ± 3.0 ms respectively and (2) a delay in LVAD flow when pump speed 
was increased which is hypothesized to be from the blood analog solution’s fluid inertia. 
Left ventricular stroke volume decreased for all LVAD pump speed modulation operating 
conditions compared to baseline (HF with LVAD off) indicating that the intelligent 
control strategy was able to reduce LV volume with increasing HVAD support. The 
highest flow was achieved with the HVAD operated at a fixed speed of 4000 rpm; 
however, co-pulsation pump speed modulation at the largest pump speed differential (low 
= 1500, high = 4000, Drpm = 2500, and systolic duration 30%) resulted in a mean pump 
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speed 3,300 ± 1,200 rpm. By comparison, the forward flow at fixed pump speed of 4,000 
rpm was 4.8 L/min compared to a mean co-pulsation rpm was 4.5 L/min. Additionally, 
all operating settings for the intelligent control during pulsatile function produced an 
average forward flow through the aortic valve, while in contrast at higher fixed speeds 
(3,500 and 4,000 rpm) the mean aortic flow was negative. Pulse pressure (DP) decreased 
with increasing mean pump speed (rpm) for all operating modes (fixed, asynchronous, 
co-pulsation, counter-pulsation). When operating at the same mean pump speed (rpm) co-
pulsation has increased hemodynamic benefit for pulsatility when compared to counter-
pulsation and fixed speed at the same mean pump (rpm). 
Conclusion: The results of this study show the ability of the intelligent HVAD 
control strategy to increase and decrease pump speed within a single cardiac cycle. This 
study showed that asynchronous modulation with phases of co-pulsation can generate 
near physiologic pulse pressure and vascular pulsatility when compared to counter-
pulsation support, while counter-pulsation can generate greater ventricular volume 
unloading and diastolic augmentation when compared to co-pulsation. Furthermore, the 
clinical impact of this study is that through speed modulation adverse events of 
continuous flow LVADs may be reduced such as incidences of bleeding associated with 
decreased pulsatility and a decrease in the risk of thrombus formation from poor washing 
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Heart failure (HF) can be defined as a chronic condition in which the heart is no 
longer able to adequately pump blood to the body to satisfy the bodies oxygen and 
nutrient demands. HF accounts for approximately 330,000 adult deaths in the United 
States annually (Benjamin et al., 2018). HF classification can be divided into four 
classes based on physical limitations as well as cardiovascular disease severity, with 
lower level classes (I-II) constituting early stage HF and higher-level classes (III-IV) 
constituting end stage HF. The classification of HF is used to determine treatment 
plans for patients depending on the progression and severity of their disease. Early 
stage HF is often treated with optimal medical management (OMM) that target HF 
symptoms and improve patient quality of life. End stage HF may also continue to be 
treated with OMM, heart transplant, and/or mechanical circulatory support, including 
an implantable left ventricular assist device (LVAD).  
LVADs are designed to augment the diseased heart in pumping blood to the body 
by pulsatile or continuous flow delivery, such as the pulsatile Thoratec HeartMate 
XVE (Abbott, Chicago, IL) LVAD and a continuous flow HeartWare HVAD 
(Medtronic, Minneapolis, MN) as shown in Figure 1.  LVADs are surgically-
implanted through open chest thoracotomy, with the device placed in the chest.  The 
2 
inflow cannula is implanted into the apex of the left ventricle (LV) and an outflow 
graft attached to the aorta (Ao) of the HF patient to deliver forward flow from the LV 
to the Ao. Electrical power and communication to the LVAD is provided through a 
driveline from the pump to an external controller that is tunneled subcutaneously and 





















Figure 1. Thoratec HeartMate XVE (pulsatile flow) (left) and Medtronic HVAD 
(continuous flow) left ventricular assist devices (LVADs). Both LVADs have a 
driveline (1) that exits the skin to communicate with the device’s controller, an 
inflow cannula (2) that is inserted into the apex of the left ventricle (LV), and an 
outflow cannula (3) that is sewn to the aorta. The HeartMate XVE propels blood 
by moving a driver bearing against a pusher plate to eject and fill the device. Blood 
flow is equal to the amount of volume that the device has and is a fluid 
displacement pulsatile LVAD. The HeartWare HVAD produces forward blood 
flow by the rotation of an impeller creating a continuous flow of blood through the 








LVADs have become a valuable tool in the treatment of advanced HF by helping 
bridge the gap between the large, growing number of advanced HF population and the 
limited number of donor hearts available for transplantation each year. LVADs have 
become more clinically accepted in recent years due to improved survival rates of 
continuous flow LVADs (CF-LVADs) being approximately 80% and 70% after one and 
two years of support respectively (Kirklin et al., 2017) comparable to heart 
transplantation survival rates. Although there are currently approximately, 2,400 LVAD 
implants a year in the US (Benjamin et al., 2018), adverse events such as bleeding, pump 
thrombosis (which could lead to stroke if the thrombus detached from the pump), 
infection, and an increased risk of developing right heart failure are associated with CF-
LVAD use (Patel et al., 2014). Infection events are more prominent immediately 
following LVAD implantation due to the surgical procedure of having an open chest 
cavity to implant the device (Patel et al., 2014). Pump thrombosis and bleeding are two 
interconnected adverse events associated with anticoagulation regiments that are 
administered to LVAD patients. Anticoagulants are administered to patients to reduce the 
risk of thrombus formation due to the patient’s blood being exposed to a foreign body 
(the LVAD); nevertheless, this therapy may increase the risk of bleeding events by 
lowering the responsiveness of the body’s natural clotting mechanisms. In addition to 
anticoagulation medications, rotary blood pumps produce high shear stress on blood and 
platelets, which has been theorized to create molecular changes in clotting factors, 
including von Willebrand factor (Patel et al., 2014), that may increase the risk of a 
clinically-significant bleeding event. The adverse events associated with CF-LVADs may 
also be due, in part, to non-physiologic volume unloading and reduction in pulsatility 
(Soucy et al., 2013) as a result of operating at fixed pump speeds.  Due to the increased 
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occurrence of these clinical adverse events with rotary blood pumps, which were not as 
commonly seen in patients with pulsatile flow devices, development of control strategies 
that enable CF-LVADs to behave more physiologically (dynamic LV volume unloading 
and pulsatility) has been proposed.  Specifically, modulating rotary pump speed (rpm) of 
CF-LVADs to create a pulse has been proposed as a potential solution to help mitigate 
the incidence of adverse events.  Modulating CF-LVAD pump speed (rpm) is achieved 
by cyclically increasing and decreasing the current that is supplied to the device. The 
current is delivered to the pump from the LVAD controller through the driveline and is 
used to set the operating pump speed (rpm) of the device.  Thus, pump speed modulation 
may be achieved by altering the current supplied to the device within a specified time 
period as opposed to operating in a continuous flow mode at a fixed pump speed. 
This thesis research tests the feasibility of pump speed modulation within a single 
cardiac cycle using the Medtronic HVAD configured with an intelligent LVAD control 
strategy in a benchtop mock circulatory loop testing platform. The intelligent control 
strategy triggers pump speed modulation with detection of an R-wave landmark from an 
electrocardiogram (EKG) to rapidly increase and decrease pump speed to produce 
dynamic LV volume unloading and pulsatile flow using a CF-LVAD rotary pump. 
 
B. Heart Failure 
1. Epidemiology 
HF has been declared a global pandemic affecting approximately 26 million people 
worldwide and nearly 6.2 million people in the United States (US, Savarese et al., 2017; 
Benjamin et al., 2019). HF prevalence in the US is expected to increase to over 8 million 
people by 2030 with an average of approximately 550,000 new cases diagnosed each year 
5 




Currently, HF is the leading cause of adult mortality in the US with nearly 330,000 
deaths reported annually (Benjamin et al., 2018). The total medical cost of care for HF 
patients is estimated at $30.7 billion dollars and is expected to increase 127% to $69.7 
billion by 2030 (Heidenreich et al., 2013), which includes medical, surgical, and re-
hospitalization expenses associated with HF therapy.   
  
2. Classification 
HF may be defined as a chronic condition with the heart losing the ability to 
adequately deliver enough blood to satisfy the oxygen and nutrient demands of the body. 
Left ventricular (LV) HF failure may be categorized as systolic and/or diastolic 
dysfunction. Diastolic dysfunction is characterized by abnormalities in the filling of the 
Figure 2: Projected heart failure population in the United States, data in this graph has been 


















Projected US Population with Heart Failure
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LV and often results in preserved ejection fraction of patients which may result from 
slowed LV relaxation and increased stiffness of the LV (Abebe et al., 2016; Paulus et al., 
2007). Systolic HF may be characterized by the diminished ability of the heart to eject 
blood within each cardiac cycle resulting in a reduced LV ejection fraction (Chatterjee et 
al., 2008). HF resulting from myocardial damage is a subset known as ischemic HF that 
is generally caused by coronary artery disease due to the decreased blood flow through 
the coronaries to the myocardium. Non-ischemic HF (NI-HF) is a subset of HF that does 
not result from coronary artery disease, but rather is characterized by myocardial damage 
leading to ventricular dysfunction. NI-HF has been hypothesized to stem from many 
potential causes not linked directly to coronary artery disease, which include but are not 
limited to infection, genetic factors, and immune system abnormalities (Wu et al., 2007).   
The New York Heart Association (NYHA) defines HF by four distinct categories 
(Table I) based on patient symptoms (including dyspnea, fatigue, or peripheral edema) 
and their inability to perform various exercise tasks (Burgess et al., 2016; Mosterd et al., 
2007). Table I lists the functional capacity and objective assessment for each heart failure 
classification based on the NYHA guidelines (Athilingam et al., 2013). Class III-IV are 
considered end stage (advanced) HF while classes I-II are considered early stage HF 
(Friedrich et al., 2007). Depending on the patient’s HF classification and the progression 
of the disease, varying medical treatments such as OMM, heart transplant, and/or 








       TABLE I 
         NEW YORK HEART ASSOCIATION HEART FAILURE CLASSIFICATION 
 
New York Heart Association (NYHA) classification of heart failure. Class I represents 
the least severe stage of heart failure with its objective assessment described by the 
NYHA and class IV describes the most severe stage of heart failure and its objective 




Due to HF having several underlying mechanisms of progression there is not one 
common cause for all HF patients. HF may be multi-variable leading to varying diseases 
of the myocardial tissue also known as a cardiomyopathy. Cardiomyopathies may be 
associated with hypertension, viral myocarditis, valvular disease, genetic predisposition, 
and coronary artery disease (CAD) (Wexler et al., 2010; Maron et al., 2006). In addition 
to these cardiomyopathies, other risk factors for the development and progression of HF 
include diabetes mellitus, aging, smoking, obesity and an excess dietary sodium intake 
(Frohlich et al., 2014). CAD is considered to be the predominant cause of ischemic HF 
and is estimated to be the underlying etiology of nearly 70% of patients (Gheorghiade et 
al., 1998). CAD is defined as the narrowing or blocking of the arteries that supply blood 
to the heart (coronaries). Reduced blood flow to the heart may result in death of 
myocardial tissue that may also lead to worsening LV function. With this subsequent 
myocardial tissue injury or death, a variety of compensatory mechanisms may be 
activated to try and maintain required cardiac output. 
 
4. Pathophysiology 
The basic underlying physiologic mechanisms in the development and progression of 
chronic HF are an initial insult (i.e. myocardial infarction) followed by ventricular 
remodeling (Delgado et al., 1999). Ventricular remodeling may be described as the 
myriad of compensatory mechanisms that subsequently take place temporally and 
spatially both in response to the dysfunction and as a consequence of the dysfunction.  
(Monreal et al., 2004)). The initial insult may reduce systolic function of the heart by 
damaging the surrounding myocardial tissue. This damage can then subsequently 
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diminish the ability of the myocardium to contract and produce blood flow to the body 
resulting in reduced cardiac output. The heart attempts to compensate for this condition 
by increasing heart rate and ventricular remodeling. Ventricular remodeling is initially an 
adaptive response to the initial insult in order to maintain pump function (Delgado et al. 
1999). However, over time the remodeling cascade progresses both temporally and 
spatially resulting in altered size, shape, and function of the ventricle through scarring, 
activation of growth factors, and molecular changes of the myocardium (Delgado et al., 
1999; Azevedo et al., 2015).  
One compensatory response to low cardiac output is known as the Frank-Starling 
mechanism.  The Frank-Starling mechanism describes the hearts ability to alter the force 
of ventricular contraction in response to venous return. By increasing the venous return of 
the heart (preload) the LV myocardium stretches allowing for greater force generation 
and contractility due to increased tension in the myocardium of the failing ventricle, 
subsequently increasing the stroke volume and cardiac output if the HR remains constant 
(Kemp et al., 2012; Sequeira et al., 2015). Additional compensation responses target the 
release of renin from the kidneys in an attempt to maintain normal renal and systemic 
perfusion by increasing the retention of water and salt; however, if this response is 
prolonged this can lead to the development of edema and increases the afterload on the 
diseased heart, furthering the progression of the disease (Delgado et al., 1999). 
Myocardial damage and worsening LV function leading to decreased contractility of the 
ventricle increases left ventricular volume, decreases stroke volume, elevates end 
diastolic pressure and volume, produces a rightward shift in the ventricular pressure-
volume (PV) relationship, and decreases aortic pressure, and pulse pressure, as illustrated 
in Figure 3.  
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Figure 3. Illustration of pressure volume (PV) loops to visualize differences between an expected 
healthy PV loop and expected heart failure (HF) PV loop (top). HF failure PV loop has distinct 
right-ward shift and increased end diastolic pressure as a result of diminished contractile strength 
and dilation of the left ventricle. Additionally, the HF PV loop has a smaller difference between 
systolic and diastolic left ventricular pressures represented in the truncation of the loop when 
compared to the expected PV loop of a healthy adult. Hemodynamic waveforms recorded in a 
mock circulatory loop to simulate a class IV HF baseline (bottom). Left ventricular end systolic 
and aortic pressures are reduced from expected healthy adult, while end diastolic pressures are 
elevated. Stroke volume or the difference between maximum and minimum left ventricular 
volume is also expected to be reduced when compared to a healthy adult. 
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5. Deviation from Normal Cardiac Physiology 
Significant changes in anatomic features and hemodynamic parameters occur in 
the transition from a healthy heart to diseased HF heart. Anatomically, the left ventricle 
becomes dilated and the myocardial walls thin (Inamdar et al., 2016). In advanced HF 
stages, left atrial pressure (mean) and left ventricular pressures (end-diastolic) increase, 
aortic and left ventricular pressures (systolic, mean) decrease, cardiac output is reduced, 
and heart rate increases, as listed in Table II (Yildiran et al., 2010; Melenovsky et al., 
2015).  As shown earlier in Figure 2, an adult with a healthy heart compared to stages of 
advanced HF will have a larger stroke volume, lower end diastolic pressure (reduced 





HEMODYNAMIC PROGRESSION OF HEART FAILURE FROM NORMAL FUNCTION 
Parameter Healthy Class I Class II Class III Class IV
Systolic Blood Pressure (mmHg)
1,2 <120 127 ± 15 123 ± 23 107 ± 15 98 ± 12
Mean Arterial Pressure (mmHg)
1,2 70-105 98 ± 10 93 ± 15 82 ± 10 77 ± 9
Diastolic Blood Pressure (mmHg)
1,2 <80 83 ± 9 78 ± 11 70 ± 9 66 ± 8
Aortic Pulse Pressure (mmHg)
1,2 ~30-40 45 ± 10 46 ± 15 37 ± 11 31 ± 9
Ejection Fraction (%)
1,2 55-75 35 ± 5 35 ± 5 28 ± 5 25 ± 5
Left Atrial Pressure (mmHg)
3,4 4-12 20 ± 8 20 ± 8 20 ± 8 20 ± 8
Heart Rate (BPM) 
1,2 65-80 81 ± 7 82 ± 14 89 ± 17 92 ± 15
Comparison of Hemodynamic Paremters
Table II displays the progression from a healthy adult to advanced heart failure. With progression of 
heart failure, the aortic blood pressure decreases during both systole and diastole, in addition to a 
decrease in the aortic pulse pressure, due to the inability of the diseased heart to generate as much force 
when compared to a healthy adult. Also, ejection fraction diminishes with progression of heart failure 
due to decreased ventricular contractility. Left atrial pressure (preload) is elevated when compared to 
healthy adults due to volume overload that takes place in heart failure patients. Finally, the heart rate is 
increased as a mechanism to attempt to increase the cardiac output with the progression of heart failure. 
Data is represented as mean +/- standard deviation and was created using data modified from Yildiran 
et al., 20101; Cleveland Clinic, Ejection Fraction2, Edwards. Normal Hemodynamic Parameters3, 2014, 
Melenovsky et al., 20154. 
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C. Treatments 
1. Medical Management 
The main objective of optimal medical management (OMM) of HF patients is to 
relieve the symptoms associated with the disease and help to improve their quality of life, 
functional capacity, and reduce the risk of hospitalization and mortality (Berliner et al., 
2017). Some pharmacological therapies for HF patients include the use of angiotensin 
converting enzyme (ACE) inhibitors (ACEIs), mineralocorticoid receptor antagonists 
(MRAs), and beta blockers (Berliner et al., 2017; Shah et al., 2017). Beta blockers 
(adrenergic receptor antagonists) are used to reduce the workload on the heart through the 
reduction in sympathetic stimulation on the heart and vasculature (Shah et al., 2017). 
ACEIs act by helping to reduce the workload on the heart by vasodilation decreasing 
peripheral resistance and to reduce the afterload that the heart has to pump against 
(Berliner et al., 2017; Shah et al., 2017). Goals of OMM for treating HF patients include 
alleviating symptoms which may impact quality of life and reducing morbidity and 
mortality of the disease. 
 
2. Heart Transplant 
The gold standard in care for patients diagnosed with advanced HF is a heart 
transplant. The first successful heart transplant was performed over 50 years ago in 1967. 
Since 1990, approximately 2,000-2,500 transplants are performed annually in the US 
(Koomalsingh et al., 2018).  Survival rates after heart transplant have steadily improved 
by approximately 10% for 1-year and 5-year survival rates when compared to the 1980s 
(Wilhelm et al., 2015), with recent data showing 1-year, 4-year, and 10-year survival 
rates at 90%, 80%, and 65%, respectively (Lund et al., 2016).   
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There are many limitations and clinical challenges associated with heart 
transplantation. Despite a slight increase in the number of transplants over past several 
years (approximately 500 additional transplants) there continues to be an insufficient 
supply of donor organs available to meet the current and projected demand estimated to 
be up to 550,000 HF patients annually (Benjamin et al., 2018). Additionally, 
comorbidities, such as irreversible pulmonary hypertension, systemic infection, inability 
to comply with the complex medical regimen, and irreversible dysfunction of the liver or 
kidneys are known contraindications (Jonge et al., 2008; Taylor et al., 2006).  Donor 
availability, organ rejection, and immunosuppression management are among the most 
common limitations associated with heart transplant therapy (Sing et al., 2015). 
 
3. Mechanical Circulatory Support 
Mechanical circulatory support (MCS) devices have been used to support NYHA 
Class III-IV patients (Katz et al., 2015). These devices have been approved for use in 
advanced HF patients as bridge to heart transplantation (BTT), bridge to recovery (BTR), 
bridge to heart transplant candidacy (BTC), and/or destination therapy (DT) (Puehler et 
al., 2014). Short-term MCS devices are currently being used as a bridge to decision in 
patients with refractory cardiogenic shock defined as the condition resulting in tissue 
hypoxia from a reduced cardiac output (Reyentovich et al., 2016). These patients may 
then be transitioned to long-term MCS or BTR. Commonly used short-term devices 
include intra-aortic balloon pumps (IABPs), Impella 2.5 & 5.0, TandemHeart, and 
extracorporeal membrane oxygenation (ECMO) (den Uil et al., 2017).  
IABPs are devices that provide diastolic augmentation using the principle of 
counter-pulsation defined by augmenting flow during diastole and reducing pressure and 
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afterload during systole of the native heart. An IABP is placed in the descending aorta.  
During diastole the balloon rapidly inflates causing blood flow to be displaced equal to 
the volume of the balloon back toward the ascending aorta to perfuse the coronary 
arteries and to the descending aorta to improve end-organ perfusion. During systole the 
balloon rapidly deflates creating a vacuum that decreases the aortic pressure, improves 
left ventricular unloading, and increases cardiac output (Gilotra et al., 2014).   
The Impella system (ABIOMED, Danvers, MA) consists of an axial rotary pump 
embedded in a catheter that is placed across the aortic valve and can deliver 2.5 to 5.0 
L/min blood flow from the LV to the aorta. The Impella 2.5 is implanted by a cardiac 
catheterization procedure, and the Impella 5.0 is implanted via a femoral cutdown. These 
devices have a pigtail-tipped catheter that sits inside the left ventricle and pumps blood 
out the ascending aorta. These devices operate asynchronously (independent of the 
cardiac cycle) and produce continuous flow to the ascending aorta (Sarkar et al., 2010).  
The Impella has been shown to be effective in patients with cardiogenic shock and 
percutaneous coronary intervention (PCI) by increasing cardiac output, reduces 
ventricular volume, and improving myocardial supply-demand ratio (Kawashima et al., 
2011; Mukku et al., 2012). 
TandemHeart (CardiacAssist Inc., Pittsburgh, PA) is a percutaneous ventricular 
assist device (pVAD) that is implanted in a left atrial to femoral artery bypass system. 
The pVAD consists of a continuous flow centrifugal blood pump and an arterial 
perfusion catheter. The pVAD draws oxygenated blood from the left atrium that is 
pumped to the systemic circulation via a femoral artery catheter to bypass the left 
ventricle of the heart (Gilotra et al., 2014). The hemodynamic benefits of pVAD use 
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include reduced LV stroke volume and LV preload while increasing cardiac output when 
compared to an IABP or Impella (Gilotra et al., 2014; Ergle et al., 2016).  
Extracorporeal Membrane Oxygenator (ECMO) therapy consists of a centrifugal 
pump and an external oxygenating system for carbon dioxide and oxygen gas exchange. 
There are two forms of ECMO based on cannulation site: (1) femoral artery and vein 
(venoarterial, VA) or (2) internal jugular vein and femoral vein (venovenous, VV). In VA 
ECMO the patient is provided with both respiratory and hemodynamic support therapy, 
whereas in VV ECMO the patients have stable hemodynamics, subsequently only 
respiratory support is required (Makdisi et al., 2015). Advantages of ECMO include the 
ability to oxygenate blood in hypoxemic states and unload both ventricles 
simultaneously. Overall the goal of short-term MCS devices is to reduce the afterload and 
preload on the failing heart while increasing cardiac output to provide better perfusion to 
the rest of the body (Gilotra et al., 2014). 
Ventricular assist devices (VADs) and total artificial hearts (TAHs) are MCS 
devices designed for long-term support. TAHs are currently approved for use in end-
stage biventricular HF as a BT. Currently, the only FDA approved TAH in the United 
States is the CardioWest TAH (SynCardia Systems, Inc, Tucson, AZ). The CardioWest 
consists of two polyurethane ventricles with stroke volumes of 70 mL. To implant the 
CardioWest TAH, (1) the ventricles are excised, (2) quick connects of the TAH are 
sutured to the valve annulus, mitral valve annulus for the left side of the heart, and the 
tricuspid valve annulus for the right side of the heart, and (3) the aortic and pulmonary 
artery grafts are then connected (Cook et al., 2015). 
LVADs may be classified as pulsatile flow VADs (PF-VADs) and CF-LVADs, 
which are both able to be implanted into the left or right ventricle by surgically grafting 
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the inflow cannula into the apex of the ventricle and the outflow graft to either the aorta 
(LVAD) or pulmonary artery (right ventricular assist device). VADs augment the heart 
by volume unloading the ventricle (reduce workload) and restoring cardiac output to 
adequately perfuse end-organs. These devices may be placed completely inside the chest, 
extracorporeally, or percutaneously. With devices placed percutaneously inflow and 
outflow cannulas are tunneled into the chest in instances of larger devices not having 
adequate room to be implanted inside the chest.  The first-generation devices were PF-
VADs that were large in size and weight, had many moving parts, and limited durability 
(Soucy et al., 2013). PF-VADs were actuated using a pneumatic driver to rapidly inflate 
and deflate an artificial membrane, such as the Thoratec PVAD (Pleasanton CA), or 
electro-mechanically using a pusher-plate mechanism, such as the Thoratec XVE 
(Pleasanton CA) to produce near-physiologic pulsatility and dynamic volume unloading.  
These devices have been replaced by second generation CF-VADs, including the 
HeartMate II (Abbott, Chicago, IL) and HeartWare HVAD (Medtronic, Framingham, 
MA), that continuously unload ventricular volume and deliver blood flow through the 
aorta by the constant fixed speed rotation of high-speed impeller (4,000-10,000 rpm) 
using axial or centrifugal design configurations. CF-VADs are smaller in size and weight, 
require fewer moving parts and no valve, and have demonstrated significantly improved 
durability (Soucy et al., 2013).  Despite the improvement in MCS device technology, 
concern with clinically-significant adverse events, including bleeding, pump thrombus, 
and stroke, may be associated (and have been hypothesized) with the non-physiologic 
conditions (small fixed volumes, diminished pulsatility) of rotary blood pumps operated 
at fixed impeller speeds. 
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D.    Challenges of VAD Support 
As MCS devices have gained widespread clinical use, common clinical 
complications and significant adverse events associated with CF-LVADs have been 
reported, including bleeding, pump thrombosis (stroke), infection, and the risk of 
developing right heart failure (Patel et al., 2014).  Bleeding has been reported in up to 
20% of HF patients supported by LVADs (Eckman et al., 2012). Acquired von 
Willebrand syndrome has been hypothesized as a potential cause of the reported high 
incidence of bleeding due to high shear stress on the blood generated by rotary blood 
pumps (Eckman et al., 2012; Nascimbene et al., 2016). Despite use of anticoagulation 
during chronic CF-LVAD support, thrombosis is another clinically-significant adverse 
event due to the risk of stroke (Eckman et al., 2012). LVAD infections are one of the 
most common adverse events with a reported incidence rate ranging from 14-28% (Rose 
et al., 2001), and which predominantly occur in the driveline for up to 19% of reported 
infections (Goldstein et al., 2012; Hernandez et al., 2017). Depending on the severity of 
the infection, clinicians may prescribe two potential treat options: (1) broad-spectrum oral 
antibiotics (Toda et al., 2015; Maniar et al., 2011) or (2) surgical intervention by either 
driveline debridement or device replacement (Hernandez et al., 2017). 
Right ventricular (RV) failure has also been reported following LVAD implantation 
with a reported incidence of 9-40% (Fida et al., 2015), which is considered a major risk 
factor in the morbidity and mortality of HF patients supported by CF-LVAD (Argiriou et 
al., 2014). RV failure may occur when the output of the right ventricle cannot achieve 
balance (or keep up with the left ventricle) resulting in high RV preload. There may also 
be a leftward shift of the intraventricular septum due to LVAD unloading, especially at 
higher pump speeds, that may also contribute to impaired RV contractility (Argiriou et 
18 
al., 2014). Treatment options for patients with RV failure include (1) OMM and/or (2) 
surgical intervention. OMM is aimed at keeping the central venous pressure less than 15 
mmHg to maintain lower RV workload using inotropes and vasodilators; additionally, the 
LVAD may be set at a pump speed that provides sufficient cardiac output without 
producing a septal shift toward the LV to help prevent detrimental RV anatomical 
changes (Fida et al., 2015; Slaughter et al., 2010). Surgical intervention consists of 
implanting a right ventricular assist device (RVAD) to support the failing right ventricle. 
Approximately 6-10% of patients with an LVAD will also receive an RVAD, resulting in 
bi-ventricular support (Bi-VAD) (Boulate et al., 2014). 
 
E. Pump Speed Modulation 
Due to the adverse events associated with continuous flow LVADs, pump speed 
modulation has been proposed to produce physiologic ventricular volume unloading and 
pulsatility. LVAD pump speed modulation is the concept of varying (increasing and 
decreasing magnitude over a defined time period or frequency) pump speed (rpm) rather 
than operating at a constant or fixed pump speed. Pump speed modulation may produce 
better (more physiologic) hemodynamics compared to continuous mode operation. Pump 
speed manipulation may also enable other operation modalities, such as timing of pump 
speed manipulation within the cardiac cycle (frequency), pump speed range with defined 
high and low settings (magnitude), time spent at each operating rpm (period), and 





1. Pump Speed Modulation: Hemodynamics 
Hemodynamic responses with pump speed modulation may vary as a function of 
LVAD operating modality, as previously shown in a mock circulatory loop (MCL) 
model. The hemodynamics for a simulated class IV HF (no LVAD), continuous flow 
using the HVAD (4000 rpm), and pulsatile flow using the HVAD (mean pump speed 
3,300 rpm) produced varying hemodynamic responses during this experiment based on 
the operating modality of the LVAD (Figure 4). Continuous flow produces decreased 
aortic pulse pressure, decreased LV stroke volume, and pulsatility when compared to 
pulsatile LVAD operation and class IV HF patients with no LVAD (Soucy et al., 2013). 
As shown in Table III, there are several benefits and limitations associated with LVAD 
pump speed modulation, including the benefits of decreasing LV workload and 
increasing pulse pressure when compared to fixed speed, but at the cost of increased 
power requirements and the risk for hemolysis with the rapid change in pump speed 
(Soucy et al., 2015). 
 


































Figure 4. Comparison of hemodynamic waveforms for class IV heart failure 
(HF) baseline recordings taken in mock circulatory loop and then left 
ventricular assist device (LVAD) operation in a continuous flow and pulsatile 
flow manner. Of note is decreased pulse pressure in both operating settings of 
LVAD but pulsatile operation creates pulse pressure (red-hue area) that is 
closer to baseline. Left ventricular volume: LVV, Left ventricular pressure: 















2. Pump Speed Modulation: Triggering 
Pump speed modulation of CF-LVADs may be accomplished using time-dependent 
variation (increase or decrease) in pump speed and triggering from an external source 
such as detection of specific landmarks within aortic pressure or EKG waveforms. 
Current examples of how pump speed modulation may be achieved, include time-based 
pump speed modulation algorithms used with Thoratec HeartMate 3 (Burlington, MA), 
Lavare cycle using the HVAD, and the Jarvik 2000 (Jarvik Heart, New York, NY) 
intermittent low speed controller. Each of these clinically approved LVADs use pump 
speed modulation to increase (or decrease) pump speed based on a set time interval of 
operation. The HeartMate 3 modulates pump speed every two seconds while the Lavare 
cycle and Jarvik 2000 modulate pump speed once per minute independent of external 
trigger or time during cardiac cycle. An additional way to trigger pump speed modulation 
Benefits Limitations
       LV work = ¯        Aortic Valve Opening = ¯
       Power = ¯        DP = ¯
       Hemolysis =  «        Adverse events
       Sensor-less control        DV = ¯
       LV work = ¯¯
       DV = ­­
      DP = ­­ •       Power = ­
      Aortic Valve Opening = ­ •       Hemolysis =  ­
       Washing = ­
       Myocardial perfusion = ­
Pulsatile 
Operation
­ = increases; ¯ = decreases; « = clinically insignificant amounts
Fixed Speed
TABLE III 
 BENEFITS & LIMITATIONS OF FIXED SPEED AND PULSATILE  
LEFT VENTRICULAR ASSIST DEVICE OPEARTION 
Table III. Benefits and limitations associated with both fixed (continuous) speed 
operation and pulsatile operation of left ventricular assist devices (LVADs). Pulsatile 
operation may have the benefits of improved pulsatility, aortic valve opening, and pump 
washing when compared to fixed speed operation while having the drawback of 
requiring more power to operate LVADs in a pulsatile fashion. Relationships in this 
table have been determined from Soucy et al., 2015. 
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is to use an external trigger, such as a pressure waveform or EKG. This technique is 
employed when using the IABP that is either triggered by the patient’s EKG or aortic 
pressure waveform to provide counter-pulsation support. Triggering from an EKG R-
wave detection algorithm is the technique employed in this study using a simulated EKG 
from a patient simulator. The intelligent control algorithm detects the R-wave on the 
EKG corresponding to ventricular contraction to increase (or decrease) pump speed. This 
technique is different from current clinically used pump speed modulation algorithms due 
to the feedback that the controller has to time the increase in pump speed from an internal 
trigger source and the specific time points in the cardiac cycle to provide support in 
asynchronous, co-pulsation, and counter-pulsation modes. The R-wave threshold 
detection for triggering pump speed modulation with the intelligent control algorithm 
used in this study is shown in Figure 5.  This threshold is set at a high enough amplitude 
for reliable R-wave detection (true positive) to avoid detection of the P or T-waves (false 
positive) and low amplitude ensure cardiac beats are not missed (false negative). 










R-Wave Detection Threshold 
Figure 5. Illustration of electrocardiogram (EKG) cartoon with R-wave detection 
algorithm threshold. Ability in intelligent left ventricular assist device (LVAD) control 
strategy to increase or decrease threshold to trigger solely from R-wave without 
interference from P or T-wave. The R-wave of the QRS complex is targeted for pump 
speed modulation triggering because it corresponds to ventricular contraction 
(depolarization) and has a distinct peak and separation from the P and T wave. The P-
wave corresponds to atrial contraction (depolarization) in the cardiac cycle while the T-
wave corresponds to ventricular filling (repolarization).   
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3. Pump Speed Modulation: Modalities 
Pump speed modulation techniques currently in clinical use focus on increasing (or 
decreasing) pump speed using an internal timing interval within the LVAD controller 
independent of the cardiac cycle. These techniques are employed in the HeartMate 3, in 
the Lavare cycle using the HVAD, and via the intermittent low speed of the Jarvik 2000 
as seen in Figure 6. The HeartMate 3 is a centrifugal flow device that is implanted inside 
the chest and provides an artificial pulse by lowering operating rpm of the pump by 2000 
rpm for 0.15 seconds and then subsequently increasing operating rpm by 4000 rpm for 
0.20 seconds before returning to the original fixed speed (Castagna et al., 2017). The 
Lavare cycle is a control strategy integrated into the HVAD to provide intermittent pump 
washing to reduce the risk of pump thrombosis. The Lavare cycle is an algorithm that 
decreases operating rpm by 200 for a period of two seconds and then increases the 
operating rpm by 400 for one second and then returns to the operating rpm of the initial 
fixed speed (Kumar et al., 2019). The Jarvik 2000 is an axial flow device and was the 
first LVAD to utilize cyclic speed rotation (one cycle per minute) to minimize the risk of 






By triggering pump speed modulation from external sources, such as the EKG or 
aortic pressure waveforms, pump speed modulation can be timed to increase (or 
decrease) pump speed at specific points in the cardiac cycle. Pump speed can be triggered 
during specific points in the cardiac cycle to produce co-pulsation (ventricular 
contraction), counter-pulsation (ventricular filling), and asynchronous (independent of 
cardiac cycle) support, as shown in Figure 6.  Pump speed modulation may be timed 
using the R-wave EKG trigger (dotted line) for co-pulsation and counter-pulsation to give 
support during specific points during the cardiac cycle, while asynchronous pump speed 
modulation is increasing (or decreasing) pump speed independent of the cardiac cycle, as 
shown in Figure 7. 
 
Figure 6. Graphical representation of pump speed modulation used by the HeartMate 3, 
Lavare cycle (HVAD), and Jarvik 2000 intermittent low speed controller. All techniques 
modulate pump speed on an internal time interval independent of cardiac cycle. HeartMate 
3 modulates pump speed every two second while the Lavare cycle and Jarvik 2000 


























Figure 7. Pump speed modulation 
based on timing increase (or 
decrease) in pump speed with 
consideration to the cardiac cycle 
recorded in a mock circulatory 
loop simulating class IV heart 
failure (HF). Asynchronous 
modulation increases (or 
decreases) pump speed 
independently of the cardiac cycle. 
Co-pulsation increases (or 
decrease) pump speed in response 
to R-wave trigger (dotted line) at 
the beginning of systole and has 
higher pump speed during 
ventricular contraction. Counter-
pulsation increases (or decreases) 
pump speed in response to R-wave 
trigger (dotted line) at the end of 
systole and has higher pump speed 
during ventricular filling. EKG: 
electrocardiogram, LVP: left 
ventricular pressure, AoP: distal 
aortic pressure, LVAD flow: left 
ventricular assist device (LVAD) 
flow, Current: current supplied to 
LVAD (controls pump speed). 
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In addition to timing pump speed modulation with respect to the cardiac cycle, 
pump speed modulation can also be achieved independent of timing (asynchronous). As 
shown in Figure 8, pump speed modulation can be controlled by increasing the Drpm 
around a fixed mean rpm (black). This strategy increases the rpm above and below a 
mean rpm that is consistent between each operating setting. Low pump speed may be set 
while the higher operating pump speed is increased, thus changing the Drpm between 
operating settings (orange). This would also in turn alter the mean pump speed, due to 
mean pump speed being a function of both high and low pump speed settings in addition 
to the time spent at each of these settings. High and low pump speed settings may also be 















Figure 8. Pump speed modulation based on varying pump speed (rpm) settings 
around a fixed mean rpm (black), set low speed while altering high pump speed 
setting (orange), and changing pump speed settings independent of target mean 
rpm or fixed high or low pump speed (blue). 
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F. Intelligent LVAD Control 
In this thesis project, a Medtronic HVAD was operated using a novel pump speed 
modulation algorithm to produce varying degrees of phasic ventricular volume unloading 
and pulsatile flow during asynchronous, co-pulsation, and counter-pulsation 
hemodynamic support in a MCL model. The HVAD was chosen because it is a clinical 
grade rotary blood pump and met the design criteria with required slew rate (defined as 
rate of change in pump speed per unit time, i.e. 1000 rpm/ms) for rapidly modulating 
(increasing, decreasing) pump speed using the supplied controller current. The intelligent 
LVAD control strategy is designed to rapidly increase (or decrease) pump speed with 
timing triggered to EKG (R-wave threshold detection) and user-defined duration (period). 
An EKG simulator was used to produce an EKG to trigger the intelligent controls pump 
speed modulation of the HVAD. The R-wave was selected as the trigger due to it 
corresponding to ventricular contraction. The percent time spent at high and low speed as 
well as the difference between high and low pump speed (rpm) were the operating 































We hypothesized that (1) co-pulsation would provide the greatest increase in forward 
flow and pulse pressure compared to fixed pump speed due to the HVAD operating at 
higher speed during ventricular contraction (systole) and pumping at the lowest pressure 
Figure 9. Illustration of intelligent left ventricular assist device (LVAD) control 
pump speed modulation controls. Pump speed has two controls the first being the 
time spent at the lower pump speed represented by 30, 35, and 40%. Also, the 
difference between high and low pump speed represented as Drpm. For this study 
the low rpm was set and the Drpm indicates the difference between the low 
setting and high setting, with the horizontal dotted line indicating the mean rpm 
of each setting. Mean rpm increased with increasing Drpm in this study due to the 
fact that the low setting was set, and the high pump speed was increasing 
thorough out this study.  
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gradient, while (2) counter-pulsation would provide the greatest decrease in ventricular 
volume and workload compared to fixed pump speed due to the HVAD operating at the 
highest pump speed during ventricular filing (diastole). We also hypothesized that the 
greater the variation in high and low pump speed (Drpm) and the longer the systolic (or 
diastolic) duration the greater the hemodynamic benefit that may be achieved.  These 
hypotheses were tested in a single-sided, mock flow loop model constructed to simulate 













A. Study Overview 
The objective of this study was to test the feasibility a novel intelligent control 
algorithm designed to rapidly increase and decrease pump speed of a LVAD (Medtronic 
HVAD, Minneapolis MN) within each cardiac cycle using a mock circulatory loop 
(MCL) model. The MCL was configured and tuned to simulate the systemic 
hemodynamics equivalent to NYHA class IV HF state in an adult. The MCL was primed 
with a blood analog solution (glycerol-saline) with a viscosity of 3 centipoise (cP) 
representing a hematocrit of 38% (Cheng et al., 2008). The goals of this study were 1) to 
demonstrate the ability to rapidly increase and decrease HVAD pump speed (rpm) within 
each cardiac cycle using R-wave trigger detection and quantifying the slew rate and 
trigger response time; 2) to identify HVAD intelligent control operating parameters the 
provide the highest degree of dynamic ventricular volume unloading, cardiac output, 
and/or vascular pulsatility; and 3) to characterize hemodynamic responses as a function 
of (a) fixed speed, synchronous systolic (co-pulsation),  and diastolic (counter-pulsation) 
timing, (b) systolic or diastolic duration (30%, 35%, 40%), and (c) modulated differential 
pump speed (Dspeed = 0, 1000, 1500, 2000, 2500 rpm).  We hypothesized that pump 
speed modulation will provide better volume unloading (rest), pulsatility (reloading), 
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and/or washing (pump, valves, ventricle) than with the LVAD operated at fixed pump 
speeds. 
B. Study Design 
1. Intelligent LVAD Control System 
The intelligent LVAD control system consists of a controller (hardware) and 
programmed algorithms (software). The intelligent HVAD control system uses a HF 
patient’s EKG waveform data to identify the R-wave landmark in real-time for every 
cardiac cycle using a threshold detection algorithm. The trigger time point (R-wave 
detection) is then used to rapidly increase or decrease user-defined pump speeds and the 
start and end time-points within the native heart cardiac cycle. The controller software 
enables the end-user to define the lower and upper pump speed settings (for a derived 
Drpm), time delay from R-wave time point, and duration of modulated pump speed cycle 
(% systole or % diastole). In this study, the intelligent control system was tested using a 
clinical grade LVAD (HVAD, Medtronic, Minneapolis, MN). The HVAD is a continuous 
flow centrifugal blood pump with a therapeutic window of 1,800 – 4,000 rpm as specified 
by Medtronic’s instructions for use (IFU). 
The control algorithm used to modulate HVAD pump speed was developed by 
Dr. Richard Wampler (Oregon Health Sciences University, Portland OR), which is 
currently protected by provisional patent (proprietary), and was implemented using 
LabVIEW (National Instruments, Austin, TX). A high-fidelity EKG waveform (1kHz) 
from a Patient Simulator (Fluke Biomedical, Everett, WA, medSim 300B) and R-wave 
detection algorithm were used to trigger an increase (or decrease) in HVAD pump speed 
by increasing (or decreasing) the current supplied to the HVAD. The software program 
provided the following user-defined input parameters via a graphical user interface 
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(GUI): (1) R-wave detection threshold (V), (2) low and high pump speeds (rpm), (3) time 
delay after successful R-wave detection to initiation of pump speed modulation sequence 
(ms), and (4) systolic duration (%).  In addition, the GUI continuously displays in real-
time the EKG waveform, R-wave trigger landmark, and pump speed. The key 









Figure 10: Medtronic HVAD centrifugal blood pump (Medtronic, Minneapolis MN). The HVAD is a 
continuous flow LVAD that operates at a clinical therapeutic window of 1,800-3,200 RPM as stated by 
HeartWare IFU (TOP). Intelligent controller (hardware) that has connections for the HVAD, a current 
measurement, and EKG input. (BOTTOM) The controller interfaces with the HVAD and intelligent 
control algorithm to allow the algorithm to visualize the EKG and detect the R-wave trigger. The 
algorithm then interfaces with the controller to increase (or decrease) pump speed based on R-wave 
detection with an additional output connection to measure the current being delivered to the HVAD 
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2. Intelligent LVAD Control Operation 
The intelligent control strategy was tested using an HVAD with left ventricular 
apical inflow and aortic outflow cannulation in the MCL model during a simulated HF 
test condition. Baseline hemodynamics were recorded with the HVAD off and outflow 
graft clamped before and after data epoch to confirm minimal (non-significant) changes 
in the HF test condition. Hemodynamic data were recorded with HVAD operated at fixed 
pump speeds (1500, 2000, 2500, 3000, 3500, 4000 rpm) and with pump speed 
modulation, each operating setting tested during this experiment is listed in Table IV.  
During pump speed modulation, the intelligent controller was set to a low pump speed 
(1500 rpm), high pump speeds (2500, 3000, 3500, 4000 rpm), and systolic (or diastolic) 
durations (30%, 35%, 40%), as illustrated in Figure 9. The operating range of high and 
low pump speeds was determined by using the therapeutic window (1,800-4,000 rpm) 
specified by the HVAD IFU. The pump speed modulation (Drpm) was defined as the 
difference between low and high pump speed settings (i.e. low = 1500 rpm, high = 4000 
rpm, Drpm =2500rpm). The intelligent LVAD control strategy was triggered from an 
EKG simulator at a constant beat rate of 80 BPM, while the MCL artificial ventricle was 
set at a beat rate of 78 BPM. This slight offset allowed for asynchronous operation of the 
intelligent LVAD control strategy, which gave multiple phases of purely asynchronous 
support, phases of co-pulsation support, and phases of counter-pulsation support over a 
four-minute test run (single data file). A single four-minute epoch (n=1) was recorded 
once for each pump setting. The order of data acquisition was fixed speed, 30% systolic 
duration, 35% systolic duration, and 40% systolic duration operating settings (note: order 
























































































Table IV. Study design of intelligent LVAD control strategy experiment. A mock 
circulatory loop (MCL) tuned to simulate class IV heart failure (HF) to (1) determine the 
capability of pump speed modulation within a single cardiac cycle, and (2) evaluate the 
hemodynamics achieved while operating the intelligent LVAD control strategy 
asynchronously with phases of co-pulsation and counter-pulsation. To accomplish these 
two objectives the intelligent LVAD control strategy operated a HeartWare HVAD at fixed 
speed and then at various Drpm and systolic durations (30%, 35%, and 40%). Systolic 
duration corresponded to the amount of time spent at the lower operating pump speed 
(1,500 rpm) during each cardiac cycle while the Drpm represents the difference between 
high and low pump speed. Each operating condition was recorded once with a four-minute 
data file (n=1). 
36 
3. Mock Loop Model 
A MCL was developed to simulate the hemodynamics of a NYHA class IV HF 
patient. The MCL was primed with a blood analog solution of glycerol (Fisher Scientific, 
G33-4, Lot 180512)-saline to simulate a viscosity range of 3.0±0.2 cP to represent a 
hematocrit of approximately 38%. Saline was created at a concentration of 0.9% using 
distilled water and sodium chloride (Fisher Scientific, L-11635). A hematocrit of 
approximately 38% was chosen to mimic the hemodilution that occurs in patients 
diagnosed with HF resulting from an increased plasma volume (Androne et al., 2003; 
Guglin et al., 2012). The viscosity of the solution was tested before the first test condition 
and repeated after completion of last test condition to validate that the viscosity did not 
change significantly over the entire time-course of the study. A viscometer (“Q” Glass 
Company, Inc., Towaco, NJ) and water bath (Thermo Scientific, Marietta, OH) were used 
to test the viscosity of the solution at 37°C by recording the transit-time of the solution 
through the viscometer. The viscosity of the solution was derived from the relationship 
between the viscosity constant, transit time, and density of the solution, as defined in 
Equation 1.  
 
 "#$%&$#'( = 0.00743 ∗ '012$#'	'#45	($5%&27$) ∗ 752$#'( 
 
The MCL was configured to simulate an adult single-sided systemic (high 
pressure) circulation with the following major components: (1) volume reservoir to 
simulate venous return, (2) inflatable balloon to simulate the compliance of the left 
atrium, (3) arterial compliance chamber, (4) pneumatically-actuated silicone sac to 
simulate the left ventricle, and (5) silicone tubing (1/8” to 3/4” inner diameter) to 
(1) 
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simulate the aorta (Figure 12).  A Sarns cardiopulmonary bypass machine (Terumo, 
Somerset, NJ) and a Sarns heater-cooler were used to maintain a physiologic temperature 
of 37°C of the blood analog solution. The construction of the MCL is representative of a 
lumped parameter model, and thereby assumes minimal losses compared to a distributed 



















Figure 12. The mock circulatory loop (MCL) used to test the intelligent HVAD control system 
consisted of a (1) volume reservoir, (2) artificial left atrium, (3) artificial ventricle, (4) arterial 
compliance chamber, (5) 1/8” to ¾” silicone tubing to simulate aorta, (6) HVAD insert into apex of 









4. Hemodynamic Measurements & Data Acquisition 
Data acquisition (DAQ) and LabChart (AD Instruments, Version 8, Colorado 
Springs, CO) were used for signal conditioning (Koenig et al., 2004), real-time A/D 
conversion (400 Hz sampling rate, 100 Hz low pass filter), visual display, and recording 
of 11 hemodynamic parameters, as shown in Figure 13. Signal conditioning of the left 
ventricular pressure (LVP) and aortic pressure (AoP) distal waveforms was performed 
using a 10 Hz low pass filter (LabChart, finite impulse response (FIR)) to reduce the 
signal noise recorded produced by the mechanical valve used in the mock loop model to 
simulate the aortic valve. Similarly, a low pass filter of 40 Hz was applied to the current 
waveform to reduce the electrical noise. The EKG waveform was amplified to an R-wave 
peak of ~2.5 volts to enable reliable threshold detection by the programmed intelligent 
control algorithm. A medSim 300B patient simulator was used to produce an EKG at a 
heart rate of 80 BPM to test the intelligent HVAD control system R-wave detection and 
pump speed modulation algorithms. Each intelligent LVAD control strategy pump 
operating setting was recorded using four-minute epochs to allow for phases of 

















Left atrial pressure (LAP) was measured using a low-fidelity (20 Hz) fluid-filled 
catheter (ARGON, Frisco, TX) and cardiac care patient monitor (Agilent, Santa Clara, 
CA). Left ventricular (LV), distal aortic pressure (AoP), and LVAD pressures were 
measured using single-tip, high-fidelity (5kHz) catheters (Millar, Houston, TX). Aortic 
root flow (AoF), total flow (TF), and VAD flow (VADF) were measured using high-
fidelity (100Hz) transit-time flow probes (Transonic Systems, Ithaca, NY). Left 
ventricular pressure-volume loops were measured using a pressure-volume admittance 
catheter (Transonic Systems, 5F, 4 segments, 10mm spacing). 
Figure 13. Data acquisition system (DAQ) with LabChart software 
used throughout the experiment to record hemodynamic waveforms.  
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Fluid-filled catheters were open to atmosphere and zeroed using the cardiac care 
patient monitor and calibrated using a TruCal Simulator/Tester (Baxter, Tulsa, OK) over 
a clinically-relevant range of pressures (-5 to 150 mmHg). Millar pressure catheters were 
pre- and post-calibrated using a digital manometer (Meriam, Cleveland, OH) and 
pressure chamber over a clinically-relevant range of pressures (-5 to 150 mmHg).  Flow 
probes were pre-calibrated electronically using a flow module calibration step (0 volt to 
1-volt (full-scale)) and factory calibration settings based upon flow probe size, mock loop 
tubing diameter, and style (in-line, clamp-on). Sample pressure and flow sensor 
















Figure 14. Illustration showing flow probe and pressure 
transducer electrical calibration. Flow probes were 
electrically calibrated using built in electrical calibration 
from flow module based on flow probe size and tubing 
diameter. Pressure transducers were calibrated by 
creating a known pressure in a pressure chamber (-5 to 
150 mmHg) and then correlating each electrical signal 
with its corresponding pressure. 
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 The pressure-volume admittance catheter was calibrated using internal electronic 
calibration settings programmed into the ADVantage PV system (Transonic, ADV500; 0 
to 400 mL, phase 0 to 20°, and mag 0 to 50 mS). The stroke volume input was set prior to 
the baseline HF recording for each set of data recordings (Table V) and was calculated by 
dividing the measured cardiac output by the beat rate of the artificial ventricle.  Pre- and 
post-calibrations were completed for all sensors and signal conditioners to verify gain and 
offset were consistent (i.e. no significant drift).  Intrinsic pump parameters that were 
recorded directly and/or derived during post-processing, included current, pump speed 
(rpm), and power. The hemodynamic parameters recorded throughout the intelligent 
LVAD control strategy experiment and the instrumentation used to acquire each 
parameter in this study are listed in Table V. The placement of each sensor within the 



























































































































































































































































































































































































































































































































The MCL was constructed and tuned to simulate hemodynamics of NYHA class 
IV HF (Yildiran et al., 2010; Melenovsky et al., 2015) with the mock LV heart rate set at 
80 bpm, systolic duration of 35%, and cardiac output of 3 L/min representative of the 
Figure 15. Schematic of mock circulatory loop (MCL) with location of each hemodynamic 
parameter recorded during the intelligent LVAD control strategy experiment.  
LA: Left Atrium    VADP: LVAD Pressure 
LAP: Left Atrial Pressure   VAD Flow: LVAD Flow 
LV: Left Ventricle    AoF: Aortic Flow 
LVP: Left Ventricular Pressure  AoP Distal: Distal Aortic Pressure 
LVV: Left Ventricular Volume 
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values seen in class IV HF patients with body mass index (ratio of weight to height: 
(kg/m2)) and cardiac index (assessment of cardiac output with respect to patients size) 
(Carlsson et al., 2012). The MCL was tuned by adjusting the preload (atrium), source 
(ventricle), and afterload (vasculature). The preload of the MCL was set by adjusting the 
height of the venous reservoir, as well as increasing the total volume of the reservoir until 
the LA pressure was within the target clinical range. The silicone mock LV pneumatic 
drive (positive) and vacuum (negative) pressures, percent systole, and beat rate were set 
using a clinical-grade pneumatic driver (P/N 500099-0006-005E Thoratec, Pleasanton 
CA). Afterload of the MCL was set by increasing (or decreasing) the peripheral 
resistance of the MCL by the closing (or opening) the turn-screw clamp (resistor) placed 
on the aorta and before the venous reservoir. 
 
5. Data Analysis  
Data were analyzed on a beat-to-beat basis with the recorded time period to 
quantify the hemodynamic performance of operating the intelligent LVAD control at 
fixed speed or in a pulsatile manner and test the proposed hypothesis that pump speed 
modulation provides improved hemodynamic support compared to HF baseline (pump 
off) and fixed pump speed. Data recorded using the intelligent control strategy to induce 
pump speed modulation were parsed into co-pulsation and counter-pulsation segments for 
each recorded four-minute asynchronous data file and each operating condition (i.e. 30% 
systolic duration at a D1000 rpm, n=1), as listed in Table IV. By operating the artificial 
ventricle at a beat rate of 78 BPM and triggering pump speed modulation using the 
intelligent LVAD control strategy at a beat rate of 80 BPM, phases of asynchronous, co-
pulsation, and counter-pulsation support were achieved in a single data file (as opposed to 
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recording three separate data files for each phase of support). To determine co-pulsation 
and counter-pulsation beat segments, the increase (or decrease) in pump current was 
aligned with the corresponding landmark of the LVP waveform. For the co-pulsation beat 
segment, a beat with an increase (or decrease) in LVAD current aligned with the 
beginning of systole, and the beats before and after were selected to create a three-beat 
co-pulsation segment. For counter-pulsation beat segments, a beat with an increase (or 
decrease) in LVAD current aligned with the end of systole, and the beats before and after 
were selected to create a three-beat counter-pulsation segment. These segments were then 
analyzed to quantify the hemodynamic performance during fixed speed, co-pulsation, and 
counter-pulsation to investigate their effect on ventricular volume unloading, cardiac 
output, and pulsatility. The hemodynamic waveforms were also graphed to evaluate the 
ability of the intelligent control strategy to modulate pump speed within a cardiac cycle. 
Data were normalized by averaging the pre- and post-calibrations of all pressure, 
flow, and volume measurements. Pre- and post-calibrations were averaged to mitigate 
any electrical drift that may have occurred during the experiment. Although minimal 
electrical drift was seen between the pre- and post-calibrations for each parameter, the 
average was still used to create the calibration factor in LabChart for each parameter 
recorded during the experiment. Once normalized, the hemodynamic data were exported 
from LabChart into text files. These texts files were saved as DAT-files, and imported 
into MatLab (R2016, Mathworks, Natick, MA) for post-processing and data reduction 
using a Hemodynamic Estimation and Analysis Research Tool (HEART) software 
(Schroeder et al., 2004). Once imported into the HEART program, each data file was 
“beat picked” using the LVP as the reference signal and a “beat picking method” that 
selected end-diastolic landmark using a threshold detection and slope algorithm, as 
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previously reported (Schroeder et al., 2004). This point on the LVP waveform 
corresponds to end diastole was used as the reference point for starting and ending each 
beat. The reference point was selected using an upper threshold, a lower threshold, a bad 
beat threshold, and an end-diastolic threshold.  Sample LVP and AoP distal waveforms 
with each beat start and end point landmark identified by a red circle on the LVP 



























































































































































































































Once each data file was “beat picked”, the file was exported as a MAT-file for 
analysis by a custom MatLab script as listed in Appendix III. The MatLab script was 
used to analyze beat-to-beat parameters for each of the 12 recorded hemodynamic 
waveforms.  The script was able to produce calculations, including max-min flow, max-
min pressure, as well as mean pressures and flows during each part of the cardiac cycle 
(systole-diastole).  
Pulse pressure (∆P), mean arterial pressure (MAP), surplus hemodynamic energy 
(SHE), energy equivalent pressure (EEP), and arterial impedance (ZART) were 
calculated from the recorded hemodynamics to quantify the impact the intelligent HVAD 
control system had on pulsatility. EEP is defined as the hemodynamic energy of a given 
volume of fluid passing through a given tubing cross section as expressed by Equation 2 
(Soucy et al., 2013). 
::; = 	
∫= ∗ ; ∗ 7'
∫= ∗ 7'
 
SHE is defined as the additional energy that exists when there is some degree of 
pulsatility in the pressure or flow waveform (Ündar et al., 2005), SHE is represented as 
the difference of EEP and MAP multiplied by 1,332 (Equation 3). 
>?:	(50@$/%4B) = 	1,332 ∗ (::; −GH;)  
ZART (vascular load impedance) is a function of resistance, compliance, and 
inertance, and regulates the dissipation of hemodynamic energy (Soucy et al., 2013). 
ZART is expressed as the fast Fourier transform (FFT) of arterial pressure divided by the 
FFT of arterial flow (Equation 4). For this experiment the resistance component of ZART 








LV stroke volume, LV external work (PV loop area), LV end diastolic pressure, 
and LV end systolic pressure were calculated to determine the effect of the intelligent 
LVAD control strategy had on ventricular volume unloading. Intrinsic pump parameters 
including speed (rpm) and current were recorded from the intelligent controller and 
analyzed. Power was calculated by multiplying the current and voltage supplied to the 
HVAD during pump operation. These parameters were used in correlation with 
hemodynamic data to visualize trends associated with increasing (and decreasing) flows 
and pressures during pump speed modulation with each cardiac cycle. Data are presented 




















A. Key Findings 
In this study, we successfully demonstrated that a novel intelligent LVAD control 
algorithm was able to increase and decrease the operating pump speed (rpm) of a 
Medtronic HVAD within a single cardiac cycle using an EKG waveform and R-wave 
threshold detection algorithm to trigger changes in pump speed. In addition, we identified 
two distinct time delays associated with the intelligent control strategy: (1) a time delay 
with initiation of changes in pump speed limitations associated with the R-wave detection 
and trigger algorithm(s), and (2) a hemodynamic time delay that occurs between the 
increase in pump speed and the increase in LVAD flow associated with fluid inertia. We 
also identified that improvements in hemodynamics with increasing levels and timing of 
pump speed modulation came at the expense of increased LVAD power consumption 
compared to operating at fixed speeds with equivalent mean flows. Notably, pump speed 
modulation improved hemodynamic performance as evidenced by dynamic LV volume 
unloading, increased cardiac output, and increased pulsatility with higher mean pump 
speed operating settings producing the greatest increases in LV volume unloading and 
cardiac output in this study, and the lower mean pump speed operating settings producing 
the greatest increases in pulsatility indices.  
 
B. Mock Circulatory Loop (MCL) Model  
We successfully demonstrated that the MCL model, used to test the performance 
of the intelligent LVAD control system, closely matched the blood viscosity and 
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hemodynamic waveforms and landmark parameters of a NYHA class IV HF patient 
(Table VI), and the viscosity of the blood analog solution was maintained at a mean of 














C. Intelligent LVAD Control –Engineering and Hemodynamic Performance 
1. Pump Speed Modulation – Engineering Benchmarks 
The intelligent LVAD control system successfully demonstrated the ability to 
rapidly increase and decrease HVAD pump speed within a single cardiac cycle during 
asynchronous operation, which also produced phases of synchronous co-pulsation and 
synchronous counter-pulsation profiles for all systolic durations (30, 35, 40%) at the 
highest pump speed profile (Drpm = 2500), as shown in Figure 17.  Specifically, the R-
wave threshold detection algorithm demonstrated the ability to trigger an increase (or 
Parameter Clinical Class IV HF MCL Achieved
Systolic Blood Pressure (mmHg) 98 ± 12 84
Mean Arterial Pressure (mmHg) 77 ± 9 63
Diastolic Blood Pressure (mmHg) 66 ± 8 46
Aortic Pulse Pressure (mmHg) 31 ± 9 38
Ejection Fraction (%) 25 ± 5 23
Cardiac Output (L/min) <3 3
Left Atrial Pressure (mmHg) 20 ± 8 23
Heart Rate (BPM) 92 ± 15 78
Comparison of Hemodynamic Paremeters
TABLE VI  
COMPARISON OF CLINICAL CLASS IV HEART FAILURE AND MOCK 
CIRCULATORY LOOP ACHIEVED HEMODYNAMICS 
Table VI. Clinical presentation of class IV heart failure hemodynamic parameters 
compared to achieved hemodynamics in mock circulatory loop. Clinical 
hemodynamic parameters are represented as mean +/- standard deviation (Yildiran et 
al., 2010; Melenovsky et al., 2015). 
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decrease) in HVAD pump speed (by the change pump current as represented by the 
dotted vertical line for each beat) and decrease (or increase) in pump speed for specified 
systolic duration prior to the next cardiac cycle (EKG waveform – QRS complex). Key 
observations during the pump speed modulation study include the following: (1) pump 
speed (current) operated independently of LV end-systole or end-diastole during periods 
of asynchronous support, (2) during periods of synchronous co-pulsation pump speed 
(current) increased at LV end-diastole, (3) during periods of synchronous counter-
pulsation pump speed (current) increased at LV end-systole, and (4) when R-wave 
detection is missed the pump speed remains at the higher operating speed until the next 
R-wave is detected.   Sample asynchronous, synchronous co-pulsation, and synchronous 
counter-pulsation waveforms for all controller settings (systolic duration, Drpm) are 



















































































































































































































































































































































































































































































































































































2. Time Delay 
Two distinct time delays were observed during pump speed modulation with the 
intelligent LVAD control system: (1) a delay in pump speed modulation despite accurate 
R-wave threshold detection, and (2) a delay in increase in LVAD flow due to the fluid 
inertia of the blood analog solution in the MCL.  
a. R-Wave Trigger Time Delay 
Ideally, the intelligent control would increase (or decrease) the HVAD pump 
speed (current, dotted vertical line, Figure 19) instantaneously upon R-wave detection; 
however, a time delay between detection of the R-wave and trigger to initiate increase (or 
decrease) of pump speed for systolic durations of 35% and 40% (Figure 18, Figure 19) 














Figure 18. A time delay between detection of the R-wave trigger and 
subsequent pump speed modulation was seen while operating the intelligent 
LVAD control strategy at systolic durations of 35% and 40%. The data 
presented is displayed as the mean. 
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Figure 19. The graphs above show MCL-acquired counter-pulsation and co-pulsation hemodynamic waveforms 
for a D2500 RPM across the 30, 35, and 40% systolic durations tested. The R-wave trigger is depicted as a vertical 
dotted line overlaying the R-wave. The time delays for 35% and 40% systolic durations are depicted as the red 
area 45 ms and 82 ms, respectively, after the R-wave.  
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b. Fluid Inertia Time Delay 
Additionally, a time delay between initiating the increase (or decrease) in pump 
speed and the resulting increase (or decrease) in LVAD flow was identified during co-
pulsation and counter-pulsation phases (Figure 20). We hypothesize that this time delay 
may be associated with an inertial effect to rapidly increase (or decrease) blood flow 
(Figure 21). The flow inertia delays were 35 ms and 187 ms for co-pulsation and counter-
pulsation, respectively.  The inertia delay will also likely be a function of patient 

















Figure 20. A time delay was observed between initiating the 
increase (or decrease) in pump speed modulation and the 
subsequent increase (or decrease) in LVAD flow for phases of 
co-pulsation and counter-pulsation support. The data presented 



















3. Slew Rate 
The pump speed slew rate was calculated for each Drpm operating setting. The 
pump speed slew rate is defined in classical engineering textbooks as the change in 
electrical current per unit time. In this study, the pump speed (rpm) was initially assumed 
to correlate with the electrical current; however, this relationship was shown to be non-
linear (Figure 22). The ability to rapidly increase (or decrease) within a cardiac cycle is 
an important design criteria, especially with increasing heart rate, which is shown in 
Figure 22. The D2500 rpm demonstrated the most rapid change in pump speed (88.5 
Figure 21. Hemodynamic waveforms for the D2500 rpm at a systolic duration of 40% operating setting to visualize 
the time delay created from the fluid inertia of the blood analog solution used in the mock circulatory loop. The 
fluid inertia delay is the delay between the increase (or decrease) in pump speed and the resulting increase in 
LVAD flow. The fluid inertia time delay is visualized as the red hued area on the waveform graph and varied 
between phases of co-pulsation (35 ms) and phases of counter-pulsation (187 ms) support. P  
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rpm/ms). The current slew rate (Figure 22) was also calculated and showed that the 
highest slew rate of 49 Amps/sec was achieved while operating the intelligent LVAD 
control at a D2500 rpm. The current slew rate increased with each increasing Drpm 
testing condition similar to the pump speed slew rate which is expected as current is the 
input to the LVAD that controls which speed the device is operating. In this study we 
demonstrated the ability to rapidly increase (or decrease) pump speed to achieve the 
desired Drpm target values. 
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Figure 22. Pump speed slew rate (top) and current slew rate (bottom) were 
calculated to evaluate if the intelligent LVAD control strategy had the 
ability to increase the rate at which pump speed is modulated at higher 
Drpm operating settings. The slew rate increased for each increase in 
Drpm resulting in the ability of the intelligent LVAD control strategy to 
modulate pump speed and current within a single cardiac cycle while 
operating at either high or low pump speed. The data presented is 
displayed as the mean.  
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D. Intrinsic Pump Parameters 
Intrinsic pump parameters (HVAD pump speed, current, and power usage) were 
obtained for all recorded test conditions. HVAD pump speed and current were recorded 
to confirm that HVAD pump speed was increasing (or decreasing) in response to 
increasing (or decreasing) the current supplied by the HVAD controller to the pump. 
HVAD power usage was recorded to evaluate if there was a penalty of increased power 
consumption while operating the HVAD in a pulsatile manner using the intelligent 
LVAD control strategy. Our results demonstrate that HVAD pump speed did increase (or 
decrease) in response to increasing (or decreasing) current and that there was a penalty of 
increased power usage when operating the HVAD in a pulsatile manner when compared 
to fixed speed operation at equivalent mean pump speeds (Table VII). 
1. Mean HVAD Pump Speed  
Mean LVAD pump speed was recorded throughout the duration of the experiment 
when operating the HVAD using the intelligent LVAD control strategy, as shown below 
in Figure 23. The highest mean pump speed while operating the HVAD using the 
intelligent control strategy in a pulsatile manner was during 30% systolic duration at a 
D2500 rpm. The mean pump speed was determined to not only be a function of the Drpm, 
but also a function of the systolic duration (or the time spent at each high and low 
operating setting), which can be visualized by the lowered mean pump speed with 
increasing systolic duration that corresponds to a shorter time spent at the higher 
operating rpm. Corresponding mean fixed speeds, depicted as horizontal red dotted lines, 
are also shown in Figure 23. Additionally, individual mean rpm values for each pulsatile 
operating setting tested using the intelligent LVAD control strategy were plotted with the 
red line depicting the mean of the data set. This graph shows the overshoot (or 
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undershoot) that occurs when operating the HVAD in a pulsatile manner with the 
intelligent LVAD control strategy. The two distinct clusters of mean rpm data points 
above and below the overall mean rpm represent the overshooting (or undershooting) of 
the desired operating rpm during pump speed modulation.  
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Figure 23. Mean pump speed (top) was plotted for each Drpm and systolic duration. Mean pump 
speed increased with increasing Drpm and was the highest at 30% systolic duration for each Drpm. 
The red dashed line (top) represents the fixed pump speed the HVAD was operated at during the 
intelligent LVAD control strategy experiment. Mean pump speed (bottom) was plotted as individual 
values on a beat-to-beat basis to show undershoot and overshoot of pump speed modulation 
throughout the entire four-minute data recording during pulsatile operation using the intelligent 
LVAD control strategy. Clusters above and below overall mean pump speed (red line, bottom graph) 
represent the over- and undershoot of the desired pump speed while operating in a pulsatile manner 
using the intelligent LVAD control strategy. It was determined that mean pump speed is not solely a 
function of the high and low pump speed settings but also as a function of the time spent (systolic 
duration) at the high and low pump speeds. Data is presented as the mean for the top graph and 
individual means for each ventricular beat on the bottom graph. 
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2. HVAD Current  
The current supplied to the HVAD from the intelligent controller was recorded 
throughout the experiment. As expected, the current increased with increasing pump 
speed operation (Figure 24). The current supplied to the HVAD is the input that either 
increases (or decreases) pump speed during operation. The highest current recorded 
during the pulsatile operation of the intelligent LVAD control strategy was during 30% 
systolic duration at a pump amplitude of D2500 rpm, which corresponds with the highest 
mean pump speed setting. Current also decreased with increasing systolic duration, 
corresponding to a lower total time spent at the higher rpm during pulsatile operation. As 
seen in the individual data point graph (Figure 24) the overshoot (or undershoot) of the 
current corresponded to the intelligent LVAD control strategy either over (or 
undershooting) the desired pump speed while operating the HVAD in a pulsatile manner. 
Also shown in Figure 24, the current and increasing pump speed (rpm) was not 
linear when operating the HVAD using the intelligent LVAD control strategy. It would 
have been expected that by increasing the magnitude of pump speed by 500 rpm each 
operating setting that the current magnitude would have increased linearly with respect to 
pump speed, due to current being the input that controls pump speed. Also, the current to 
power relationship is more curvilinear than the current to rpm relationship due to power 
being derived by squaring the current and then multiplying it by the internal coil 






























Figure 24. Mean current (top) supplied to the HVAD was plotted for each Drpm and systolic 
duration during pulsatile operation and at each fixed speed operating setting during 
continuous operation. Mean current supplied to the HVAD increased with increasing Drpm 
and was the highest at 30% systolic duration for each Drpm and follows the same trend as 
mean pump speed. Current supplied to the HVAD is the input that dictates what pump speed 
the LVAD will operate at. Mean current (bottom) supplied to the HVAD was also plotted as 
individual values on a beat-to-beat basis to show over- and undershoot of current supplied to 
the HVAD during pump speed modulation throughout the entire four-minute data recording 
for each pulsatile operating setting. As seen in the bottom graph continuous operation does 
not demonstrate any over- or undershoot of current supplied to the HVAD, but while 
operating in a pulsatile manner the clusters of data above and below the overall mean current 
(red line, bottom graph) indicate an over- or undershoot of current supplied to the HVAD 
during pump speed modulation. Data is presented as the mean for the top graph and 
individual means for each ventricular beat on the bottom graph. 
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3. HVAD Power  
The power of the HVAD during this experiment was derived by multiplying the 
current squared by the internal resistance of the HVAD pump used in this study. The 
internal coil resistance of the HVAD was 4.8 ohms and was multiplied by the current 
squared that was supplied to the HVAD to acquire total estimated power. HVAD power 
usage on average was greater while operating in a pulsatile manner using the intelligent 
LVAD control strategy when compared to mean pump speeds at equivalent mean pump 
flows (Table VII) with the exception of operating the intelligent control strategy at a 
systolic duration of 40% with D2000 and D2500 rpms. This could be explained due to 
these two operating settings not corresponding exactly to a fixed speed operating setting 
tested in this experiment. Power followed the same trend as mean pump speed, and 
current with the higher the Drpm had the higher power requirement compared to systolic 
durations (Figure 25). By plotting the data points individually, we are able to demonstrate 
intelligent LVAD control over- and undershooting desired operating pump speed (Figure 
25) leading to a larger range of power use when compared to fixed speed operation. By 
correcting this over (or undershoot) of pump speed while in pulsatile operation, the power 
difference between pulsatile operation and corresponding fixed speed mean pump speed 



























Figure 25. Mean HVAD power usage (top) was plotted for Drpm and systolic duration during 
pulsatile operation and at each fixed speed operating setting during continuous operation. 
Mean HVAD power usage increased with increasing Drpm and was the highest at 30% 
systolic duration for each Drpm and follows the same trend as mean pump speed and current 
supplied to the HVAD. HVAD power usage on average is higher during pulsatile operation 
while modulating pump speed using the intelligent LVAD control strategy when compared to 
an equivalent mean pump speed. Mean HVAD power usage (bottom) was also plotted as 
individual values on a beat-to-beat basis to show over- and undershoot of HVAD power usage 
during pump speed modulation throughout the entire four-minute data recording for each 
pulsatile operating setting. As seen in the bottom graph continuous operation does not 
demonstrate any over- or undershoot of power usages, but while operating in a pulsatile 
manner the clusters of data above and below the overall mean HVAD power usage (red line, 
bottom graph) indicate an over- or undershoot of HVAD power during pump speed 
modulation. Data is presented as the mean for the top graph and individual means for each 








E. Pump Speed Modulation – Hemodynamic Performance 
Within a select 10-second data epoch of asynchronous operation phases during 
co-pulsation and counter-pulsation support were achieved for single, isolated cardiac 
cycles. In between these time points, asynchronous support occurred independent of the 
cardiac cycle to produce beat-to-beat changes in hemodynamic parameters. The 
hemodynamic support achieved for pulsatility, LV volume unloading, and cardiac output 
were determined for each type of support (co-pulsation, counter-pulsation, and fixed 
speed). The operating condition that provided the greatest degree of ventricular volume 
unloading, highest increase of total and LVAD flow, highest preserved aortic flow, and 





























TABLE VII  
POWER DIFFERENCE BETWEEN PULSATILE OPERATION USING THE INTELLIGENT 
LVAD CONTROL STRATEGY AND EQUIVALENT FIXED SPEED MEAN RPM 
Table VII. Power usage difference of each pulsatile operating setting compared to its 
equivalent mean fixed pump speed operating setting. Power usage on average was higher for 
pulsatile operation when compared to continuous operation of the HVAD using the intelligent 
LVAD control strategy. The negative power usage difference for D2000 and D2500 while 
operation at a systolic duration of 40% may be attributed to these settings not having a true 
equivalent fixed speed to compare against, as these two settings mean pump speeds lying in 
between the fixed speed operating settings tested. Data is presented as the percent difference 
between pulsatile operating settings and equivalent fixed speed operating settings. 
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greatest degree of pulsatility with its specific achieved hemodynamic values (Table VIII). 
Overall, operating the intelligent control at a D2500 rpm (highest mean rpm) resulted in 
the greatest degree of ventricular volume unloading, the highest increase in total flow, 
and the highest increase in LVAD flow. The greatest increase in aortic flow and greatest 
degree of pulsatility parameters were achieved by operating the intelligent control at a 




























































































Table VIII. Operating settings for the greatest degree of ventricular volume unloading, increase in total flow 
and LVAD flow, and greatest degree of pulsatility are shown on the left side of the table with the 
hemodynamics achieved for each operating setting listed on the right side of the table. Operating settings that 
have higher mean pump speeds produced the greatest degree of ventricular volume unloading and increases in 
total and LVAD flow. Operating settings that have lower mean pump speeds produced the greatest degree of 
pulsatility and greatest forward flow through the aortic valve. Data is presented as the mean. 
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1. Left Ventricular (LV) Volume Unloading 
Stroke volume decreased for all HVAD pump speed modulation operating 
conditions compared to baseline (HF, HVAD off) as shown in Figure 26. However, our 
experimental findings did not demonstrate the large reductions in LV unloading we had 
hypothesized (smallest stroke volume, achieved at 4000 rpm fixed speed). This may have 
been due in part to a significant error associated with LV volume measurement we 
identified during data analysis and troubleshooting. This error as well as a potential 
calculation error (MatLab script, Appendix III) likely resulted in erroneous LV external 
work (equals DLV volume * DLV pressure) results. First error, the LV volume 
admittance catheter did not have the required number of segments and appropriate 
spacing to accurately measure the volume of the mock ventricle. Second error, 
calculation of LV systolic and diastolic pressures (average) and forward flow (LV stroke 
volume) may have resulted in an under estimation of these values. To address this error, 
we modified our methods and performed additional data analysis using LabChart’s 
software. The LabChart calculation of LV external work appeared to be a better 
estimation based upon the rough estimation of the area within the PV loop (LV stroke 
volume * (LV end systolic pressure – LV end diastolic pressure)). 
LV end diastolic pressure was also reduced with increasing mean rpm for all 
pump settings (fixed, pulsatile asynchronous operation), as shown in Figure 26. 
Additionally, increasing Drpm provides a greater degree of volume unloading during both 
phases of co-pulsation and counter-pulsation support (Figure 26), which may also be 
attributed to the increase in mean pump speed when increasing Drpm in this study. The 
mean pump speed (rpm) for counter-pulsation and co-pulsation is a function of the 
systolic duration (time spent at each rpm) and Drpm.  
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Pressure-volume (PV) loops recorded for each operating setting tested while 
operating the intelligent LVAD control strategy at a fixed speed are shown in Figure 27. 
The PV loops did not produce a downward shift to the left as would be expected with 
increasing LVAD support for any testing condition (fixed or pulsatile operation). It is 
believed that the size of the LV volume catheter used in this study was inadequate and 
did not allow for the measuring of LV volume throughout the entirety of the artificial 
ventricle. The LV volume catheter limitations may explain (in part) why the end diastolic 
and end systolic volumes appear to condense around the center of the NYHA class IV HF 










































































































































































































































































































































































































































2. Cardiac Output 
As shown in Figure 28, the highest flow was achieved with the HVAD operated at 
a fixed speed of 4000 rpm; however, during phases of asynchronous co-pulsation pump 
speed modulation at the largest pump speed differential (low = 1500, high = 4000, Drpm 
= 2500, systolic duration 30%) mean pump speed was the greatest (3,300 ± 1,200 rpm). 
The forward flow at a fixed pump speed of 4,000 rpm was 4.8 L/min compared to a mean 
co-pulsation rpm of 4.5 L/min.  Mean total flow increased for all pump speed modulation 
operating settings with increasing mean rpm and Drpm. Co-pulsation on average yielded 
Figure 27. Left ventricular pressure-volume (PV) loops recorded during fixed speed operation 
of the HVAD using the intelligent LVAD control strategy. The PV loops for the fixed speed 
operation are representative of each operating setting tested during this study. The PV loops 
did not shift downward or to the left with increasing LVAD support as would be expected. The 
limitations (inadequate of number and spacings of electrodes) of the LV volume catheter used 
in this study may explain (in part) why the PV loops did not respond to increasing LVAD 
support as would have been expected. 
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the highest total forward flow at equivalent mean pump speed (rpm) when compared to 
counter-pulsation at the same mean pump speed (rpm). Increasing systolic duration 
(lower total time spent at higher rpm) flow decreased due to the reduction in mean pump 
speed (rpm), as shown in Figure 28. 
The operating setting that had the greatest aortic flow occurred at a D1000 rpm 
and a systolic duration of 40%, with phases of co-pulsation having a greater preservation 
of aortic flow when compared to phases of counter-pulsation at the same Drpm (Figure 
28). Regurgitant flow was seen through the aortic valve when operating the HVAD at 
fixed pump speeds greater than 3,500 rpm. In contrast to fixed speed operation of the 
HVAD, there was no regurgitant flow observed when modulating pump speed in a 
pulsatile manner with the intelligent LVAD control strategy, independent of Drpm or 




























































































































































































































































































































































Pulse pressure (DP) decreased with increasing mean pump speed (rpm) for all 
operating settings (fixed speed and modulating pump speed asynchronously). The 
operating setting that achieved the smallest reduction in pulse pressure from HF baseline 
occurred at a D1000 rpm and 40% systolic duration, with phases of co-pulsation 
producing higher pulse pressures than counter-pulsation at the same Drpm (Figure 29). 
The operating setting that resulted in the greatest aortic pressure pulsatility index (PI) was 
achieved using the intelligent HVAD control strategy at a D1000 rpm with a systolic 
duration of 35%, with phases of co-pulsation producing greater PI than phases of counter-
pulsation.  
SHE, a measure of the extra energy that is produced by pulsatile blood flow, is 
reduced in HF patients that are implanted with a CF-LVAD (Soucy et al., 2013). The 
operating setting that produced the greatest SHE was at a D1000 RPM at a systolic 
duration of 40%, with phases of co-pulsation generating higher SHE values than phases 
of counter-pulsation. Vascular resistance was also calculated and increased with 
increasing mean rpm from baseline in all operating settings and was higher in co-
pulsation when compared to counter-pulsation at the same mean pump rpm. Increasing 
mean pump speed (rpm) decreased pulsatility parameters (Figure 29). When operating at 
the same operating setting (equivalent mean pump speed), phases of co-pulsation showed 
increases in pulsatility as evidenced by increases in AoP DP, PI, and SHE compared to 








Figure 29. Aortic pulse pressure (AoP DP, top-left) reduced with increasing DRPM as expected due to the 
subsequent increase in mean pump speed as well. Phases of co-pulsation produced greater pulse pressures than 
counter-pulsation and fixed speed operation at equivalent mean pump speeds. Surplus hemodynamic energy 
(SHE, bottom-left) reduced with increasing DRPM and followed the same trend as the AoP DP with co-
pulsation producing greater SHE values at equivalent pump speeds. The aortic pressure pulsatility index (PI, 
top-right) reduced with increasing operating RPM due to the decrease in AoP DP. Vascular resistance (R, 
bottom-right) increased with increasing DRPM with fixed speed operation producing greater vascular resistance 




F. Hemodynamic Trade-Offs  
While evaluating the hemodynamics achieved using the intelligent LVAD control 
strategy, hemodynamic trade-offs were observed between operating settings that gave the 
highest degree of LV volume unloading, largest increase in cardiac output, and highest 
degree of pulsatility achieved. Our results indicate it may be possible to operate the 
intelligent LVAD control strategy to target specifically LV volume unloading, cardiac 
output, and/or pulsatility support directly. But with the ability to target each type of 
hemodynamic support directly there may also be hemodynamic trade-offs incurred. 
1. Left Ventricular Volume Unloading 
During this experiment the operating setting that produced the greatest degree of 
LV volume unloading by evaluating reductions in LV stroke volume, LV end diastolic 
pressure, and LV external work was operating the intelligent LVAD control strategy 
asynchronously at a D2500 rpm at a 30% systolic duration while in phases of counter-
pulsation. This operating setting corresponded to the highest mean pump speed 
throughout the experiment and produced the greatest degree of LV volume unloading 
while also increasing cardiac output but came with the limitations of decreasing 




















2. Cardiac Output 
Cardiac output had the greatest augmentation in total flow, LVAD flow, and 
aortic flow when the intelligent LVAD control strategy was operating asynchronously, 
during phases of co-pulsation at a D2500 rpm with a systolic duration of 30%. Operating 
at this setting gave the largest increase in cardiac output and greatest degree of LV 
volume unloading but came at the limitations of reduced pulsatility and increased HVAD 
power usage, as shown in Table X. The aortic flow did not follow this trend (increase in 
mean pump speed results in increased total and LVAD flow), as it was generally greater 
at lower mean pump speeds. Due to the aortic flow always having a mean forward flow, 
the operating setting that gave the highest degree of augmentation in cardiac output 
occurred with pump setting of  D2500 rpm, systolic duration of 30%, and during phases 
of co-pulsation support. 
Table IX. Hemodynamic trade-offs of operating the intelligent LVAD 
control strategy to produce the greatest degree of left ventricular (LV) 
volume unloading. Cardiac output is also increased while operating the 
intelligent LVAD control strategy to produce the greatest LV volume 
unloading but diminished pulsatility and increased power usage of the 
LVAD. 
TABLE IX 





↑ = Increases; ↓ = Decreases

















The highest degree of pulsatility was achieved while operating the intelligent 
LVAD control strategy asynchronously at a D1000 rpm at 40% systolic duration during 
phases of co-pulsation as evidenced by increases in AoP DP, PI, SHE, and vascular 
resistance. This operating setting corresponded to the lowest mean pump speed tested 
while operating the HVAD in a pulsatile manner using the intelligent LVAD control 
strategy. The highest degree of pulsatility had hemodynamic trade-offs, including lower 
LV volume unloading and cardiac output with the increased power requirements while 
operating the HVAD in a pulsatile manner (Table XI). 
 
 
TABLE X  
CARDIAC OUTPUT HEMODYNAMIC TRADE-OFFS 
LV Volume Unloading ↑
Pulsatility ↓
Power ↑
↑ = Increases; ↓ = Decreases
∆2500 RPM at 30% Systolic Duration:
during Co-Pulsation Phases
Table X. Hemodynamic trade-offs of operating the intelligent LVAD 
control strategy to produce the greatest increase in cardiac output. Left 
ventricular volume unloading also increased while operating the intelligent 
LVAD control strategy to produce the greatest increase in cardiac output 
but diminished pulsatility and increased power usage of the LVAD. The * 
designates that LV volume unloading would be expected to increase in this 
operating setting due to operating at a high mean pump speed; but due to 
limitations associated with the LV volume catheter the degree to which the 













TABLE XI  
PULSATILITY HEMODYNAMIC TRADE-OFFS 
LV Volume Unloading ↓
Cardiac Output ↓
Power ↑
↑ = Increases; ↓ = Decreases
∆1000 RPM at 40% Systolic Duration:
during Co-pulsation Phases
Table XI. Hemodynamic trade-offs of operating the intelligent LVAD 
control strategy to produce the highest degree of pulsatility. Left ventricular 
volume unloading and cardiac output decreased in order to obtain the 
highest degree of pulsatility in this study while operating the HVAD using 
the intelligent LVAD control strategy. In addition to reducing the degree of 
left ventricular volume unloading and augmentation of cardiac output there 
was also an increase in power usage of the LVAD. The * designates that 
LV volume unloading would be expected to decrease in this operating 
setting due to operating at a lower mean pump speed; but due to limitations 
associated with the LV volume catheter the degree to which the LV is 








A. Key Findings 
In this study, we successfully demonstrated that a novel intelligent LVAD control 
strategy reliably detected an R-wave from an external EKG and triggered pump speed 
(rpm) modulation (rapidly increase and decrease) of a Medtronic HVAD within a single 
cardiac cycle. However, unexpectedly the relationship between electrical current and 
pump speed (rpm) was non-linear for unknown reasons, which may be associated with 
limitations of the intelligent LVAD controller. The results of this study also demonstrated 
that mean operating pump speed (rpm) is a function of (1) magnitude of change in pump 
speed (Drpm) and (2) time spent at the high and low operating pump speeds (rpm). The 
HVAD pump speed modulation settings that produced the greatest ventricular volume 
unloading, greatest increase in cardiac output, and greatest pulsatility (DP, SHE) were 
identified. Counter-pulsation provided the greatest ventricular volume unloading 
compared to co-pulsation at the same mean pump speed (rpm) as characterized by a 
greater reduction in LV end diastolic pressure and LV external work.  Phases of co-
pulsation support produced the greatest pulsatility and cardiac output compared to phases 
of counter-pulsation at the same mean pump speed (rpm) as characterized by a greater 
aortic pulse pressure, pulsatility index, surplus hemodynamic energy, total flow, and 
LVAD flow. During post-processing and data analysis of the recorded hemodynamic 
waveforms for all test conditions, two unexpected time delays were identified: (1) a 
computational time delay (ms) between the detection of the R-wave threshold landmark 
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and the command to initiate rapid increase in pump speed associated with an algorithm 
implementation error, and (2) a hemodynamic time delay between the increase in pump 
speed and increase in LVAD flow associated with fluid inertia. 
 
B. Pump Speed Modulation 
1. Thoratec HeartMate 3: Artificial Pulse 
The Thoratec HeartMate 3 (Burlington, MA) is a clinically-approved centrifugal 
LVAD that is implanted inside the chest with the inflow cannula sutured to the LV and 
the outflow cannula routinely grafted to the aorta. The HeartMate 3 provides an artificial 
pulse by lowering the operating rpm of the pump by 2000 rpm for 0.15 seconds, followed 
by an increase in operating rpm by 4000 rpm for 0.20 seconds, and then lowered to the 
original fixed pump speed (Figure 30). The HeartMate 3 pump speed modulation 
algorithm operates asynchronously to the native heart to create an artificial pulse that 
transitions in and out of phase with the native heart cardiac cycle resulting in flow 
reduction (counter-pulsation) phase and flow augmentation (co-pulsation) phases 
(Castagna et al., 2017), but cannot be set to function continuously in co-pulsation and 








Figure 30. Graphical representation of the Thoratec HeartMate 3 pump speed modulation 
technique. Pump speed modulation occurs once every two seconds independent of the cardiac 
cycle with a 2000 rpm decrease in pump speed for 0.15 seconds followed by a 4000 rpm increase 
in pump speed for 0.20 seconds and then returning to original fixed speed until next pump speed 
modulation cycle. 
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In a study performed by Krabatsch et al., clinical outcomes data for 50 patients 
implanted with the HeartMate 3 were follow-up at one-year post-implant to evaluate 
incidence of adverse events, re-hospitalizations, device malfunction, and survival 
(Krabatsch et al., 2017). The study concluded lower rates of pump thrombosis (no 
incidence), GI bleeds (12%), and no pump failures (mechanical) compared to the reported 
adverse events (INTERMACS) of patients supported with other currently available CF-
LVADs. Although the author reports no incidence of hemolysis and/or pump thrombosis, 
the overall rate of stroke was 18% (Krabatsch et al., 2017). The findings in the study 
conducted by Krabatsch et al., may support that the pump speed modulation of the 
HeartMate 3 may reduce the risks of GI bleeds and pump thrombosis. Additional studies 
with durations spanning longer than a year may need to be done in order to see if pump 
speed modulation is the main contributing factor to the reduced incidence of adverse 
events for the patients implanted with the HeartMate 3.  
 
2. Lavare Cycle: Medtronic HVAD 
The Lavare cycle is a control strategy integrated into the Medtronic HVAD 
controller designed to provide intermittent pump washing to help reduce the risk of pump 
thrombosis. The Lavare cycle is a pump speed modulation algorithm that rapidly 
decreases pump operating speed by 200 rpm for a period of two seconds, followed by a 
rapid increase of 400 rpm for one second, and then rapid decrease back to the initial set 
pump speed (Figure 31). The Lavare cycle is intended to reduce the occurrence of 
thrombus formation by potentially decreasing the areas of blood stasis within the LV by 










The hypothesis that the Lavare cycle may decrease the potential for thrombus 
formation by reducing blood stasis in the LV is supported by the findings of Zimpfer et 
al. They demonstrated that operating a Medtronic HVAD with the Lavare cycle 
decreased the stagnation index of the LV by 22% compared to operating at a fixed pump 
speed in a MCL model with particle image velocimetry (PIV) analyses (Zimpfer et al., 
2016). They also found that a drop-in pump speed greater than 400 rpm produced 
negative flow at the inflow cannula. It is theorized that larger drops in pump speed and/or 
longer periods of support at low pump speed settings may promote aortic valve opening 
and reduce the risk of GI bleeds by promoting pulsatile flow compared to CF-LVADs 
(Zimpfer et al., 2016).   
 
3. Jarvik 2000: Intermittent Low Speed (ILS) 
The Jarvik 2000 (Jarvik Heart, New York, NY) is a clinically-approved axial flow 
LVAD that is implanted with the inflow and outflow grafts attached to the LV and 
ascending aorta, respectively. The Jarvik 2000 was the first LVAD to use cyclic pump 
speed rotation (one cycle per minute) to minimize the risk of thrombus formation by 
promoting periodic ejection through the aortic valve, as described in the Jarvik 2000’s 
Figure 31. Graphical representation of the Medtronic HVAD pump speed modulation technique using the 
Lavare cycle. The Lavare cycle operates asynchronously to the native heart with a pump speed modulation 
cycle that occurs once per minute. The Lavare cycle decreases pump speed by 200 rpm for two seconds and 
then increases the operating rpm by 400 rpm for one second before returning to the original fixed pump 
speed. 
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operating manual (Figure 32). By reducing the operating pump speed of the Jarvik 2000 
for a short period of time with the ILS controller, the amount of pump flow and LV 
unloading is reduced, and the workload of the heart is increased. During this short period 
of time, in which the Jarvik pump operates at lower pump speeds, the heart adapts to the 
increase in preload by increasing contractility (Selzman et al., 2018). The native heart is 
able to eject a greater volume of blood through the aortic valve, which may result in 
better washing of the aortic valve and root, thereby reducing the risk of aortic thrombus. 
The Jarvik 2000 ILS controller may also have the added benefit of an increase in 











Stanfield et al. conducted a study implementing a MCL to compare two bearing 
designs for the Jarvik 2000 during support with the ILS algorithm (Stanfield et al., 2013), 
and demonstrated average flow was reduced by up to 68% but produced up to 360% 
increase in PI for both bearing designs (Stanfield et al., 2013). The finding in this in vitro 
study evaluating the intelligent LVAD control strategy supports the theory that a 
Figure 32. Graphical representation of the Jarvik 2000 intermittent low speed (ILS) pump speed 
modulation technique. The ILS pump speed modulation technique operates asynchronously to the 
native cardiac cycle and reduces operating rpm of the Jarvik 2000 for a short period of time each 
minute to allow the native heart to retake the majority of work in pumping blood to the body before 
returning to the original fixed pump speed.  
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reduction in pump speed should result in increased pulsatility that may offer the benefits 
of a more physiologic flow pattern and potentially a reduced risk of AI formation, but at 
the potential expense of decreasing the degree of LV volume unloading and cardiac 
output.  
C. Clinical Impact 
The potential clinical impact of this study is the implementation of an intelligent 
LVAD control strategy to provide pump speed modulation of CF-LVADs with the ability 
to provide pulsatile flow in an asynchronous manner with phases of counter-pulsation and 
co-pulsation support. Pump speed modulation is a function of mean pump speed (rpm) as 
well as magnitude of rapid changes in pump speed (Drpm) and time period (T, ms) at 
high and low pump speed settings. Additionally, effective pump modulation settings may 
also be able programmed to provide greatest LV volume unloading, cardiac output, 
and/or pulsatility based upon patient-specific needs. If the time delays (or advances) are 
implemented into the intelligent LVAD control strategy, pump speed modulation may 
target specific phases of the cardiac cycle, such as co-pulsation or counter-pulsation. For 
example, if the mean pump speed (rpm) during a pulsatile mode (pump speed 
modulation) was kept constant and the magnitude (Drpm) increased around that mean 
setting, then counter-pulsation would be expected to have greater hemodynamic benefit 
with respect to LV external work and LV end-diastolic pressure compared to the same 
co-pulsation mean pump speed (rpm). Also, co-pulsation would be expected to have a 
greater hemodynamic benefit for pulsatility and cardiac output when evaluating pulse 
pressure, PI, SHE, and total flow if the mean pump speed (rpm) if pulsatile operation of 
the intelligent control was kept constant and the Drpm was increased around the same 
mean compared to counter-pulsation support.  The ability to specify type of pump speed 
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modulation support (co-pulsation, counter-pulsation, and asynchronous) specific to a 
patient’s need (ex. activity level and time of day) may also be possible to achieve.  
A complication that is often present in long-term CF-LVAD support is the 
development or progression of aortic insufficiency (AI). AI can develop as a result of the 
pressure gradient applied across the aortic valve limiting the opening of the valve due to 
the implantation of CF-LVADs. This can result in partial opening or closure of the aortic 
valve followed by subsequent distortion of the aortic valves anatomy. (Cowger et al., 
2010). In our mock loop study, we did not identify any regurgitant flow through the 
mechanical aortic valve in the MCL model while operating the Medtronic HVAD in a 
pulsatile fashion, but regurgitant flow was observed when operating the HVAD at fixed 
speeds greater than 3,500 rpm (regurgitant flow up to ~0.75 L/min). This finding supports 
the concept that pump speed modulation allows better aortic valve opening by allowing 
the heart to produce forward flow through the aortic valve as a result of a lowered 
pressure gradient across the aortic valve and may help to reduce the incidence of AI but 
needs to be evaluated further utilizing in vivo testing platforms to see the effect on a 
biological aortic valve. 
Although there are potential benefits to pump speed modulation, a drawback 
associated with operating CF-LVADs in a pulsatile manner may be the incidence of 
bleeding from the potential of increasing the shear stress that is applied to the blood and 
platelets. Bleeding has been hypothesized to occur due to high shear stress on blood 
causing acquired von Willebrand syndrome from the continuous rotation of CF-LVAD 
impellers (Eckman et al., 2012). Additional studies evaluating the intelligent LVAD 
control strategy for blood trauma should be done to evaluate if pump speed modulation of 
CF-LVADs increases the risk of bleeding due to the shear stress that can be applied to 
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blood and platelets during pump speed modulation.  Also, with the high shear stresses 
applied on blood hemolysis and platelet damage may occur leading to thrombus 
formation may result.    
 
D. Limitations 
By testing the intelligent LVAD control strategy in a MCL model, many 
assumptions and associated limitations may impact interpretation of key findings.  First, 
the MCL model was configured and tuned to mimic key hemodynamic parameters of a 
class IV HF patient. Although the MCL model is a valuable tool in the pre-clinical testing 
of MCS devices, it cannot reproduce the interactions between a biological system and the 
device (HVAD). Second, the MCL is a lumped parameter model and does not have the to 
simulate the complex branching network of the circulatory system (multiple vessels, 
length, diameter, wall thickness), which may impact vascular pulsatility.  Third, the MCL 
model does not account for physiologic feedback mechanisms (i.e. Frank Starling, 
baroreceptor), thereby limiting evaluation of how intelligent control algorithm 
performance and physiologic responses to a dynamic cardiovascular system (ex. 
vasoconstriction and vasodilation). Fourth, a blood analog (glycerol-saline) solution 
rather than human blood was used, subsequently biological considerations such as blood 
trauma, hemolysis, and clotting, were not investigated. Despite these limitations, the 
MCL provides a valuable benchtop testing platform to test the feasibility of pump speed 
modulation algorithm and hemodynamic performance of the intelligent LVAD control 
strategy as an initial step in the pre-clinical development phase required to demonstrate 
function, efficacy, reliability, and safety (verification and validation) prior to clinical 
implementation. 
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 A technical limitation of this study was the inability to reliably synchronize the 
intelligent control algorithm with the cardiac cycle of the mock ventricle, which limited 
operation to asynchronous mode.  However, short periods of co-pulsation and counter-
pulsation phases were achieved when setting mock ventricle (78 bpm) and intelligent 
control algorithms (80 cycles/sec), which were instrumental in elucidating the two 
unexpected time delays (trigger, inertia effect).  The computational delay (trigger) can be 
easily corrected in software, and the inertial delay may be corrected by enabling user to 
adjust initiation (advance or delay) of pump speed increase (or decrease), similar to an 
IABP console. The ability to modulate pump speed comes at the expense of requirement 
for increase in power, which may reduce the amount of time the device can be operated 
solely on battery power.  
An instrumentation limitation of this study was the use of the volume admittance 
catheter which did not have the appropriate number of segments and spacings required to 
accurately measure the entire volume of the mock ventricle. The volume catheter used in 
this study did not allow for the measurement of volume throughout the entirety of the 
artificial ventricle, but only at the apex. Additionally, the MatLab calculation of LV 
external work from the product of the LV systolic and diastolic pressures (averages) and 
forward flow (LV stroke volume) may have resulted in an under estimation of the LV 
external work. To address this error, we modified our methods and performed additional 
data analysis using LabChart’s software. These limitations may explain why the LV 
stroke volume, LV external work, and PV loops did not vary largely with increasing 
mean pump speeds as would have been expected.  
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Finally, a limitation of the study design was that only single recordings for each 
test condition were completed. Subsequently, it did not allow the ability to test for 
reproducibility (larger sample size) and statistical analysis between operating settings.  
 
E. Future Considerations 
Next steps for the intelligent LVAD control strategy include additional testing in a 
MCL to evaluate the ability to reproduce the data gathered in this experiment and also 
increase the sample size to allow for statistical analysis of the data collected. 
Additionally, a time delay (or advance) could be implemented to account for the time 
delays observed in this study; (1) a computational time delay (ms) between the detection 
of the R-wave threshold landmark and the command to initiate rapid increase in pump 
speed associated with an algorithm implementation error, and (2) a hemodynamic time 
delay between the increase in pump speed and increase in LVAD flow associated with 
fluid inertia. This delay (or advance) would facilitate more accurate pump speed ramping 
in response to specific points in the cardiac cycle that would allow pump speed 
modulation not only in an asynchronous manner but also specifically for co-pulsation and 
counter-pulsation support. A time delay (or advance) that allows for specified support 
would allow the ability to gather data for co-pulsation, counter-pulsation, and 
asynchronous support independently, giving the ability to compare and contrast each type 
of support for LV volume unloading, cardiac output, and pulsatility. In future 
experiments in which the intelligent LVAD control strategy is able to target support 
based on specific points in the cardiac cycle the heart rate at which pump speed 
modulation is triggered can be altered. The study design of future experiments can also 
be changed to evaluate the intelligent LVAD control strategy at varying heart rates to 
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investigate if the intelligent control strategy can modulate pump speed within a cardiac 
cycle at higher heart rates. The effect of arrhythmias on the intelligent LVAD control 
strategy should be investigated to see how the control algorithm responds to various 
arrhythmias such as ventricular tachycardia. Finally, safety measures should be 
implemented into the intelligent control algorithm for events such as ventricular wall 



























The results of this study show the ability of the intelligent LVAD control strategy 
to increase and decrease pump speed within a single cardiac cycle. This study showed 
through asynchronous modulation that phases of co-pulsation can generate near 
physiologic pulse pressure and pulsatility when compared to phases of counter-pulsation. 
Counter-pulsation phases generated greater ventricular volume unloading when compared 
to phases of co-pulsation. Furthermore, the clinical impact of pump speed modulation of 
CF-LVADs may result in lower incidence of adverse events associated with CF-LVAD 
support such as bleeding and aortic insufficiency but additional testing needs to be 
performed in order evaluate the effectiveness of pump speed modulation in living 
systems. Additional studies implementing the time delays (or advances) need to be done 
in order to show proof of concept in providing co-pulsation and counter-pulsation 
support. Also, with the ability to specify pump support the hemodynamic benefits can be 
evaluated for each type of support, as well as investigating if it is more beneficial to 
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APPENDIX I HEMODYNAMIC WAVEFORMS:
Asynchronous waveforms for a 30% systolic duration: 
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Counter-pulsation & CO-pulsation waveforms for a 35% systolic duration: 
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APPENDIX II HEMODYNAMIC GRAPHS: 









APPENDIX III MATLAB SCRIPT FOR INTELLIGENT CONTROL ANALYSIS:
MatLab Script for Intelligent Control experiment analysis 
% This file is adapted from hrt_VAD.m which was originally written by 
% Steven Koenig, Ph.D. on November 6, 2001 for the HEART program to 
analyze 
% Mock Circulatory Loop data from CorWave initial testing. 
% 
% This file calculates beat-to-beat hemodynamic parameters of mat files 
% that were outputted by HEART. AoP or LVP beats must have been picked in 
% HEART. 
% 
% Update 2/28/17 - Calculations for AOP, SHE, EEP have been changed to used 
% LVP beat indices (more reliable), and LVP end systolic pressure is now 
% calculated based on timing (mock loop timing is more reliable; less noise). 
% 






folderpath = 'S:\CII Unrestricted\Cary Data Dump 
Zone\2019_Data\Jake_Thesis\30sys\mat\'; % Set to directory of mat files **NEED 
trailing \ 
d=what(folderpath);  % Get everything in directory 
filename=d.mat; % Gets all .mat files in the current folder 
  
errors = 0; % initialize to no errors 
  
% List all output labels that you are saving in heartData at the bottom of 
% the code. This is to set up an output matrix for later export to Excel 
% document. DO NOT REMOVE 'Recording'. 
labelList = {'Recording' 'Heart Rate' 'Cardiac Output' 'Ejection Fraction',... 
            'Mean LAP' 'LAP Systolic' 'LAP Diastolic',... 
            'Mean LVP' 'LVP Peak Systolic' 'LVP End Systolic' 'LVP End Diastolic' 
'LVP +dP/dt' 'LVP -dP/dt',... 
            'LVV End Systole' 'LVV End Diastole' 'LVV Stroke Volume' 'LV External 
Work',... 
            'Mean AoP' 'AoP Systolic' 'AoP Diastolic' 'DeltaP_AoP'  'Mean AoF',... 
            'Max AoF' 'Min AoF' 'AoF Systolic Avg' 'AoF Diastolic Avg',... 
            'Mean AoPd' 'AoPd Systolic' 'AoPd Diastolic',...  
            'Mean VAD P' ' VAD P Systolic' 'VAD P Diastolic' 'Mean VAD F' 'Max 
VAD F' 'Min VAD F' 'VAD F Systolic Avg' 'VAD F Diastolic Avg',... 
            'Mean TotalFlow' 'TotalFlow peak (+)' 'TotalFlow peak (-)' 'TotalFlowPI' 
'ZART' 'SHE' 'EEP' 'ArtPavg' 'ArtPsys' 'ArtPdia' 'DeltaP_ArtP' 'ArtP_PI' 'LVCO'}; 
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% Set up output matrix for later export to Excel document. 
for i=1:length(labelList) 








numFiles = length(filename); 
progress = 0; 
h = waitbar(progress,'Initializing data...'); 
  
for k=1:length(filename)                        % Run for all files in folder 
    load(strcat(folderpath,filename{k}))        % Load the .mat files one by one 
    n=filename{k};                              % Get filename of current .mat file 
    outputName = strcat(n(1:end-15),'-analysis'); 
    if k == 1 
        prevName = outputName; 
        currentFile = 1; 
    else  
        if (strcmp(outputName,prevName) == 0) 
            output = output.'; 
            xlswrite(prevName, output, 'Sheet1'); 
            output = {}; 
            for i=1:length(labelList) 
                output(i,1) = labelList(i); 
            end 
            prevName = outputName; 
            currentFile = 1; 
        else 
            currentFile = currentFile + 1; 
        end 
    end 
  
  
    if isempty(LVPbeatindices) == 1 
        % return error of no data to analyze 
        disp(strcat('No LVP beat indices found in .mat file: ',n)) 
        errors = 2;  
    else % analyze 
        numbeats = size(LVPbeatindices,1); 
         
        % Change HEART variables to real names 
         AoPd = P1; % AOP Distal 
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        VADF = VASF; % VAD Flow 
        VADP = P2; % VAD Pressure 
        TotalFlow = F1; %Total Flow 
        AOPRF = AoF % %Root Flow 
        AOPRM = ArtP % Root Millar 
        Current = Mrkr 
        Phase = T 
        MAG = Gz 
        AOPRF = AoP 
        
        % Initialize data variables 
        LVHR = zeros(numbeats,1)*NaN; 
        LVppdPdt = zeros(numbeats,1)*NaN;        
        LVpndPdt = zeros(numbeats,1)*NaN; 
        LVPbd = zeros(numbeats,1)*NaN;               
        LVPavg = zeros(numbeats,1)*NaN;    
        LVPed = zeros(numbeats,1)*NaN;   
        LVPpksys = zeros(numbeats,1)*NaN; 
        LVPes = zeros(numbeats,1)*NaN; 
        LVEW = zeros(numbeats,1)*NaN; 
        LVVes = zeros(numbeats,1)*NaN;           
        LVVed = zeros(numbeats,1)*NaN;           
        LVVSV = zeros(numbeats,1)*NaN;            
        LVEF = zeros(numbeats,1)*NaN; 
        AoPavg = zeros(numbeats,1)*NaN; 
        AoPsys = zeros(numbeats,1)*NaN; 
        AoPdia = zeros(numbeats,1)*NaN; 
        ArtPavg = zeros(numbeats,1)*NaN; 
        ArtPsys = zeros(numbeats,1)*NaN; 
        ArtPdia = zeros(numbeats,1)*NaN; 
        ArtP_PI = zeros(numbeats,1)*NaN; 
        LAPsys = zeros(numbeats,1)*NaN; 
        LAPdia = zeros(numbeats,1)*NaN; 
        LAPavg = zeros(numbeats,1)*NaN; 
        AoPdsys = zeros(numbeats,1)*NaN;         
        AoPddia = zeros(numbeats,1)*NaN; 
        AoPdavg = zeros(numbeats,1)*NaN; 
        LCAPsys = zeros(numbeats,1)*NaN;         
        LCAPdia = zeros(numbeats,1)*NaN; 
        LCAPavg = zeros(numbeats,1)*NaN; 
        CdAPsys = zeros(numbeats,1)*NaN;         
        CdAPdia = zeros(numbeats,1)*NaN; 
        CdAPavg = zeros(numbeats,1)*NaN; 
        SpinalPsys = zeros(numbeats,1)*NaN;         
        SpinalPdia = zeros(numbeats,1)*NaN; 
        SpinalPavg = zeros(numbeats,1)*NaN; 
        RenalPsys = zeros(numbeats,1)*NaN;         
        RenalPdia = zeros(numbeats,1)*NaN; 
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        RenalPavg = zeros(numbeats,1)*NaN; 
        AoFavg = zeros(numbeats,1)*NaN; 
        AoFpkpos = zeros(numbeats,1)*NaN; 
        AoFpkneg = zeros(numbeats,1)*NaN; 
        AoFsys = zeros(numbeats,1)*NaN; 
        AoFdia = zeros(numbeats,1)*NaN; 
        LAFavg = zeros(numbeats,1)*NaN; 
        LAFpkpos = zeros(numbeats,1)*NaN; 
        LAFpkneg = zeros(numbeats,1)*NaN; 
        LAFsys = zeros(numbeats,1)*NaN; 
        LAFdia = zeros(numbeats,1)*NaN; 
        CAFavg = zeros(numbeats,1)*NaN; 
        CAFpkpos = zeros(numbeats,1)*NaN; 
        CAFpkneg = zeros(numbeats,1)*NaN; 
        CAFsys = zeros(numbeats,1)*NaN; 
        CAFdia = zeros(numbeats,1)*NaN; 
        CdAFavg = zeros(numbeats,1)*NaN; 
        CdAFpkpos = zeros(numbeats,1)*NaN; 
        CdAFpkneg = zeros(numbeats,1)*NaN; 
        CdAFsys = zeros(numbeats,1)*NaN; 
        CdAFdia = zeros(numbeats,1)*NaN; 
        SAFavg = zeros(numbeats,1)*NaN; 
        SAFpkpos = zeros(numbeats,1)*NaN; 
        SAFpkneg = zeros(numbeats,1)*NaN; 
        SAFsys = zeros(numbeats,1)*NaN; 
        SAFdia = zeros(numbeats,1)*NaN; 
        RAFavg = zeros(numbeats,1)*NaN; 
        RAFpkpos = zeros(numbeats,1)*NaN; 
        RAFpkneg = zeros(numbeats,1)*NaN; 
        RAFsys = zeros(numbeats,1)*NaN; 
        RAFdia = zeros(numbeats,1)*NaN; 
        AoFdavg = zeros(numbeats,1)*NaN; 
        AoFdpkpos = zeros(numbeats,1)*NaN; 
        AoFdpkneg = zeros(numbeats,1)*NaN; 
        AoFdsys = zeros(numbeats,1)*NaN; 
        AoFddia = zeros(numbeats,1)*NaN; 
        LVCO = zeros(numbeats,1)*NaN; 
        VADPsys = zeros(numbeats,1)*NaN;         
        VADPdia = zeros(numbeats,1)*NaN; 
        VADPavg = zeros(numbeats,1)*NaN; 
        VADFavg = zeros(numbeats,1)*NaN; 
        VADFpkpos = zeros(numbeats,1)*NaN; 
        VADFpkneg = zeros(numbeats,1)*NaN; 
        VADFsys = zeros(numbeats,1)*NaN; 
        VADFdia = zeros(numbeats,1)*NaN; 
        TotalFlowavg = zeros(numbeats,1)*NaN;          
        TotalFlowpkpos = zeros(numbeats,1)*NaN;        
        TotalFlowpkneg = zeros(numbeats,1)*NaN;         
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        TotalFlowpulse = zeros(numbeats,1)*NaN;         
        TotalFlowsv = zeros(numbeats,1)*NaN; 
        TotalFlowPI = zeros(numbeats,1)*NaN; 
        ZARTbt = zeros(numbeats,1)*NaN; 
        SHE =zeros(numbeats,1)*NaN;  
        SHEbt = zeros(numbeats,1)*NaN;    
        EEP =zeros(numbeats,1)*NaN; 
        EEPbt = zeros(numbeats,1)*NaN;       
         
        fs = 400 
        dt = 1/fs;  % Fetch sampling interval and create dt (time interval) 
         
        % Filters - requires Signal Processing Toolbox  
        % See https://www.mathworks.com/help/curvefit/smooth.html 
        AoPfilt = fastsmooth(AoP,20,2); 
        AoPfilt = fastsmooth(AoPfilt,20,2); 
        ArtPfilt = fastsmooth(ArtP,20,2); 
        ArtPfilt = fastsmooth(ArtPfilt,20,2); 
        LAPfilt = fastsmooth(LAP,20,2); 
        LAPfilt = fastsmooth(LAPfilt,20,2); 
        
         
        % Force flow units to be ml/sec 
        AoF = AoF*1000/60;      % Aortic flow 
        VADF = VADF*1000/60;    % VAD flow 
        TotalFlow = TotalFlow*1000/60 
    
         
         
        plotcheck = 0;                  % Set to 1 to see verification plots and values. 
  
        for counter = 1:(numbeats)                                                   
            if LVPbeatindices(counter,3) == 1                               % Do only 'good' 
beats 
                btstart = LVPbeatindices(counter,1);                        % Beginning of 
LVP beat 
                btend = LVPbeatindices(counter,2);                          % End of LVP beat 
                btlen = btend-btstart+1; 
                 
                % Calculate heart rate  
                LVHR(counter,1) = 60/((btend-btstart)*dt); 
                percentSystole = .35; % percent systole set on the ventricle driver, will 
change between heart conditions 
                indexEndSys = round(btstart + 
((60/LVHR(counter,1))*percentSystole)/dt); 
                 
                index35 = round(btstart + 0.35*(btend-btstart));      % Index at 35% of 
beat length (ref. to pt 1) 
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                index80 = round(btstart + 0.8*(btend-btstart));       % Index at 80% of 
beat length (ref. to pt 1) 
                index120 = round(btstart + 1.2*(btend-btstart));      % Index at 120% of 
beat length (ref. to pt 1) 
  
% Stroke volume routine not needed in SecondHeart study                 
                % Calculate stroke volume in mL 
                % Use TotalFlow for mock loop testing 
                if exist('TotalFlow') == 1 
                   %  Offset flow  
                   AoFoffset=mean(TotalFlow(index80:btend)); 
                   AoFnew = TotalFlow;%-AoFoffset;          % offsets flow  
                   [fmax ifmax] = max(AoFnew(btstart:btend));              
  
                   % find start pt. of flow 
                   indexback=0; 
                   while AoFnew(btstart+ifmax+indexback-1)>0 && 
(btstart+ifmax+indexback-1)>btstart 
                       indexback = indexback-1; 
                   end   
                   flowb=btstart+ifmax+indexback-1; 
  
                   % find end pt. of flow 
                   indexfor=0; 
                   while AoFnew(btstart+ifmax+indexfor-1) > 0 && 
(btstart+ifmax+indexfor-1) < btend 
                       indexfor = indexfor+1; 
                   end   
                   flowe=btstart+ifmax+indexfor-1; 
  
                   %   Calculate the SV in mL 
                   % LVSV(counter,1) = trapz(AoFnew(flowb:flowe))*dt; % IGNORES 
NEGATIVE FLOW 
                   LVSV(counter,1) = trapz(AoFnew(btstart:btend))*dt; 
                end             
  
                % Calculate left ventricular parameters (+dP/dt,-dP/dt,Pbd,Ped,Ppksys) 
                if exist('LVP') == 1  
                    % Calculate the slope of LVP at each data point for beat 'counter' 
                    LVslopes=[]; 
                    LVslopes(1:(btlen),1) = [1/(12*dt)]*[LVP(btstart-2:btend-2,1)-
8*LVP(btstart-1:btend-1,1)+8*LVP(btstart+1:btend+1,1)-LVP(btstart+2:btend+2,1)]; 
  
                    % Calculate peak positive (dP/dt) and peak negative (-dP/dt) LVP 
pressure as an 
                    % index of contractility using previous 'slope' routine 
                    [LVppdPdt(counter,1),LVmaxsi] = max(LVslopes); % LVmaxsi = 
max slope index  (within bt. index) 
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                    [LVpndPdt(counter,1),LVminsi] = min(LVslopes); % LVminsi = min 
slope index  (within bt. index)  
  
                    % Calculate LV diastolic beginning (LVPbd) and ending 
(LVPed)pressures and LV systolic pressure 
                    postol = 100;      % set high threshold for LVPed 
                    negtol = 0;        % set low threshold for LVPbd 
                    maxLVPbd=30;       % set max. LVPbd pressure threshold 
                    LVPbtstep = LVminsi; %create pt by pt increment counter 'step' to 
find LVPbd pt                                                     
                    while LVslopes(LVPbtstep,1) < negtol % find LVPbd pt 
                        LVPbtstep = LVPbtstep + 1; 
                        if LVPbtstep >= btlen, break, end; % error check - if can't find 
LVPbd at slope = 0 
                    end 
  
                    LVPbd(counter,1) = LVP(btstart+LVPbtstep-1);                    % 
Calculate Pbd = LVP beginning diastole     
                    LVPavg(counter,1) = mean(LVP(btstart:btend)); 
                    LVPed(counter,1) = LVP(btend);         % Calculate Ped = LVP end 
diastole at end of beat 
                    [LVPpksys(counter,1),indexMaxLVP] = max(LVP(btstart:btend-1));  
% Calculate LVPsys = LV systolic pressure (max LVP) 
                    %[LVPpksys(counter,1),indexES] = max(LVP(btstart:btend-1)); 
                    [LVPes(counter,1),indexEnS] = max(LVP(indexEndSys-
15:indexEndSys+15)); 
                    indexED = btend; 
                    indexES = indexEndSys - 15 + indexEnS; 
                end   
  
                % Calculate LV external work 'LVEW'(ref Sunagawa, 1983) 
                % Use TotalFlow for mock loop testing 
                if exist('LVP') == 1 && exist('AoF') ==1 
                    negtol = 0; 
                    bstep = LVminsi;                                                      
                    while LVslopes(bstep,1) < negtol;  bstep = bstep + 1;  if bstep >= 
btlen,    break, end; end 
                     
                    [fmax ifmax] = max(AoF(btstart:btend)); 
                    % find start pt. of flow 
                    indexback=0; 
                    while AoF(btstart+ifmax+indexback-1)>0 && 
(btstart+ifmax+indexback-1)>btstart 
                        indexback = indexback-1; 
                    end   
                    flowb=btstart+ifmax+indexback-1;  
  
                    % find end pt. of flow 
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                    indexfor=0; 
                    while AoF(btstart+ifmax+indexfor-1) > 0 && 
(btstart+ifmax+indexfor-1) < btend 
                        indexfor = indexfor+1; 
                    end   
                    flowe=btstart+ifmax+indexfor-1; 
                      
                    LVPdavg = mean(LVP(btstart+bstep-1:btend));     % LVP avg. 
diastolic pressure. Temp. variable. 
                    LVPsavg = mean(LVP(flowb:flowe));               % LVP avg. systolic 
pressure. Temp. variable. 
                    LVEW(counter,1) = sum((LVP(flowb:flowe)-
LVPdavg).*AoF(flowb:flowe)).*dt;    % New EW method. 
                end           
  
                % Calculate LV end-systolic, end-diastolic, and stroke volumes 
                if exist('LVV') == 1  
                    LVVed(counter,1) = max(LVV(btstart:btend)); 
                    LVVes(counter,1) = min(LVV(btstart:btend)); 
                    LVVSV(counter,1) = LVVed(counter,1)-LVVes(counter,1); 
                    LVEF(counter,1) = LVVSV(counter,1) / LVVed(counter,1) * 100; 
                end 
  
  
                % This routine is used to calculate aortic root peak systolic, min 
diastolic, and mean pressures 
                if exist('AoP') == 1 
                    if LVPbeatindices(counter,3) == 1 
                       btstartAo = LVPbeatindices(counter,1);    
                      btendAo = LVPbeatindices(counter,2); 
                      btlenAo =  btendAo-btstartAo+1;  
                        AoP(indexES+5:indexED) = AoPfilt(indexES+5:indexED); 
                      AoPavg(counter,1) = mean(AoP(btstartAo:btendAo)); 
                        % Grab AoPsys point using the LVPsys index 
                        AoPsys(counter,1) = AoP(indexES); 
                        AoPdia(counter,1) = AoP(indexED); 
                        DeltaP_AoP = AoPsys - AoPdia; 
                    end 
                end 
                 
                 if exist('ArtP') == 1 
                    if LVPbeatindices(counter,3) == 1 
                       btstartArt = LVPbeatindices(counter,1);   
                      btendArt = LVPbeatindices(counter,2); 
                      btlenArt =  btendArt-btstartArt+1;  
                        ArtP(indexES+5:indexED) = ArtPfilt(indexES+5:indexED); 
                      ArtPavg(counter,1) = mean(ArtP(btstartArt:btendArt)); 
                        % Grab AoPsys point using the LVPsys index 
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                        ArtPsys(counter,1) = ArtP(indexES); 
                        ArtPdia(counter,1) = ArtP(indexED); 
                        DeltaP_ArtP = ArtPsys - ArtPdia; 
                        ArtP_PI = DeltaP_ArtP/ArtPavg 
                    end 
                end 
                 
                progress = progress + ((1 / numFiles) * .325 * (1 / numbeats)); 
                progressText = num2str(progress*100,'%.2f'); 
                waitText = strcat(progressText,'% complete... 
(',num2str(k),'/',num2str(numFiles),' files analyzed)'); 
                waitbar(progress,h,waitText) 
                 
                % This routine is used to calculate LA max systolic, min diastolic, and 
mean pressures 
                if exist('LAP') == 1  
                    %LAP(indexES+5:indexED) = LAPfilt(indexES+5:indexED); 
                    LAPsys(counter,1) = LAP(indexES); 
                    LAPdia(counter,1) = LAP(indexED); 
                    LAPavg(counter,1) = mean(LAP(btstart:btend-1)); 
                end 
                 
                if exist('AoPd') == 1  
                    AoPdsys(counter,1) = AoPd(indexES); 
                    AoPddia(counter,1) = AoPd(indexED); 
                    AoPdavg(counter,1) = mean(AoPd(btstart:btend-1)); 
                end 
                if exist('VADP') == 1  
                    VADPsys(counter,1) = VADP(indexES); 
                    VADPdia(counter,1) = VADP(indexED); 
                    VADPavg(counter,1) = mean(VADP(btstart:btend-1)); 
                end 
                 
                if exist('AoF') ==1 
                    AoFavg(counter,1) = mean(AoF(btstart:btend))*60/1000;              % 
calculate mean flow 
                    AoFpkpos(counter,1) = max(AoF(btstart:btend))*60/1000;             % 
calculate peak positive flow 
                    AoFpkneg(counter,1) = min(AoF(btstart:btend))*60/1000;             % 
calculate peak positive flow 
                    AoFsys(counter,1) = mean(AoF(btstart:indexES));                    % 
calculate average systolic flow 
                    AoFdia(counter,1) = mean(AoF(indexES:btend));                      % 
calculate average diastolic flow 
                end 
                  
                if exist('VADF') ==1 
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                    VADFavg(counter,1) = mean(VADF(btstart:btend))*60/1000;              
% calculate mean flow 
                    VADFpkpos(counter,1) = max(VADF(btstart:btend))*60/1000;             
% calculate peak positive flow 
                    VADFpkneg(counter,1) = min(VADF(btstart:btend))*60/1000;             
% calculate peak positive flow 
                    VADFsys(counter,1) = mean(VADF(btstart:indexES));                    % 
calculate average systolic flow 
                    VADFdia(counter,1) = mean(VADF(indexES:btend));                      
% calculate average diastolic flow 
                end 
                 
                 if exist('TotalFlow') ==1 
                    TotalFlowavg(counter,1) = mean(TotalFlow(btstart:btend))*60/1000;              
% calculate mean flow 
                    TotalFlowpkpos(counter,1) = 
max(TotalFlow(btstart:btend))*60/1000;             % calculate peak positive flow 
                    TotalFlowpkneg(counter,1) = 
min(TotalFlow(btstart:btend))*60/1000;             % calculate peak positive flow 
                    TotalFlowsys(counter,1) = mean(TotalFlow(btstart:indexES));                    
% calculate average systolic flow 
                    TotalFlowdia(counter,1) = mean(TotalFlow(indexES:btend));                      
% calculate average diastolic flow 
                    TotalFlowPI = ((TotalFlowpkpos - TotalFlowpkneg)/TotalFlowavg); 
                end 
                 
                
                % Calculate SHE and EEP and ZART beat-to-beat 
                if exist('ArtP') == 1 && exist('TotalFlow') ==1 
                     if LVPbeatindices(counter,3) == 1 
                        btstartArtP = LVPbeatindices(counter,1);     
                        btendArtP = LVPbeatindices(counter,2); 
                        ArtPmbt(counter,1) = mean(ArtP(btstartArtP:btendArtP)); 
                        EEPbt(counter,1) = 
(trapz(ArtP(btstartArtP:btendArtP).*TotalFlow(btstartArtP:btendArtP))*dt)/(trapz(TotalF
low(btstartArtP:btendArtP))*dt); %in mmHg 
                        if EEPbt(counter,1) < 0 
                            EEPbt(counter,1) = NaN; 
                        end 
                        SHEbt(counter,1)=1332*(EEPbt(counter,1)-ArtPmbt(counter,1)); 
%units = ergs/cm^3 
                        if SHEbt(counter,1) < 0 
                            SHEbt(counter,1) = NaN; 
                        end 
                        EEP (counter,1) = 
(trapz(AoP.*TotalFlow)*dt)/(trapz(TotalFlow)*dt); 
                        MAP (counter,1)= mean(AoP); 
                        SHE (counter,1)= 1332*(EEP(counter,1)-MAP(counter,1)); 
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                        % BEGIN ZART beat-to-beat  
                        ArtPdynes=ArtP*1333;          %converting to dynes/cm^2 
                        thresh = 0.02; % set fractional threshold on flow fft magnitude 
                        fftstart=btstartArtP; 
                        fftend=btendArtP; 
                        epochl = fftend-fftstart+1;                         % length of epoch being 
analyzed 
                        xxx=fft(ArtPdynes(fftstart:fftend-1))/(epochl-1);         % pressure 
fft 
                        yyy=fft(TotalFlow(fftstart:fftend-1))/(epochl-1);   % flow fft 
                        ZZZ=xxx./yyy;                                       % input impedance in 
dyne-sec/cm5 
                        ZARTbt(counter,1) = ZZZ(1);                         % ZART is the input 
impendence at 0Hz (first harmonic; DC term) 
                    end 
                end 
  
                %Plotting routine to verify correction waveform analysis 
                if plotcheck==1; figure 
                    %Check LVP 
                    plotys(LVP(btstart:btend)); hold on 
                    hline = refline([0 LVPavg(counter,1)]); hline.Color = 'r'; 
                    
plot(find(LVP(btstart:btend)==LVPpksys(counter,1),1,'last'),LVPpksys(counter,1),'ro');  
                    
plot(find(LVP(btstart:btend)==LVPed(counter,1),1,'last'),LVPed(counter,1),'ro'); pause 
                    close 
                    % Check Ao 
                    plotys(AoP(btstart:btend)); hold on 
                    hline = refline([0 AoPavg(counter,1)]); hline.Color = 'r'; 
                    
plot(find(AoP(btstart:btend)==AoPsys(counter,1),1,'last'),AoPsys(counter,1),'ro');  
                    
plot(find(AoP(btstart:btend)==AoPdia(counter,1),1,'last'),AoPdia(counter,1),'ro'); pause 
                    close 
                    % Check AoPd 
                    plotys(AoPd(btstart:btend)); hold on 
                    hline = refline([0 AoPdavg(counter,1)]); hline.Color = 'r'; 
                    
plot(find(AoPd(btstart:btend)==AoPdsys(counter,1),1,'last'),AoPdsys(counter,1),'ro');  
                    
plot(find(AoPd(btstart:btend)==AoPddia(counter,1),1,'last'),AoPddia(counter,1),'ro'); 
pause 
                    close 
                end 
                 
            end % End of good beat if-statement 
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        end % End of beat by beat 'counter' loop 
         
       
        progress = progress + (1 / numFiles * .325); 
        progressText = num2str(progress*100,'%.2f'); 
        waitText = strcat(progressText,'% complete... 
(',num2str(k),'/',num2str(numFiles),' files analyzed)'); 
        waitbar(progress,h,waitText) 
  
        % Calculate cardiac output = sv x hr as a single matrix 
        % multiplication. Use TotalFlow for mock loop with VAD study. 
        if exist ('LVV') == 1 
            LVCO = LVVSV.*LVHR/1000; % Use for flows recorded in L/min (that 
were calculated into mL/sec) 
%              LVCO = LVSV.*LVHR;     % Use for flows recorded in mL/min (that 
were converted to mL/sec) 
        end 
         
        heartData = [LVHR LVCO LVEF LAPavg LAPsys LAPdia, ... 
                     LVPavg LVPpksys LVPes LVPed LVppdPdt LVpndPdt LVVes 
LVVed LVVSV LVEW, ... 
                     AoPavg AoPsys AoPdia DeltaP_AoP AoFavg AoFpkpos AoFpkneg 
AoFsys AoFdia,... 
                     AoPdavg AoPdsys AoPddia,... 
                     VADPavg VADPsys VADPdia VADFavg VADFpkpos 
VADFpkneg VADFsys VADFdia,... 
                     TotalFlowavg TotalFlowpkpos TotalFlowpkneg TotalFlowPI EEPbt 
SHEbt ZARTbt,... 
                     ArtPavg ArtPsys ArtPdia DeltaP_ArtP ArtP_PI LVCO]; 
                     
                      
         
        for i=2:numbeats+1 
            for j=1:length(labelList)-1 
                beatOutput{i,j} = heartData(i-1,j); 
            end 
        end 
         
        xlswrite(outputName, beatOutput, n(1:end-4)); 
         
        beatOutput = {}; 
        for i=2:length(labelList) 
            beatOutput(1,i-1) = labelList(i); 
        end  
                  
        stats = []; 
        [row,col] = size(heartData);   
        for column = 1:col 
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            data = heartData(:,column); 
            stats(column,1) = nanmean(data(isfinite(data)));    
            stats(column,2) = std(data(isfinite(data)));    
        end 
        errors = 0; 
    end % End of 'isempty' if statement for analysis block (LVP beat check) 
     
    output{1,currentFile*2} = strcat(n(1:end-4),' Means'); 
    output{1,currentFile*2+1} = strcat(n(1:end-4),' Std Devs'); 
    for i=2:length(labelList) 
        output{i,currentFile*2} = stats(i-1,1); 
        output{i,currentFile*2+1} = stats(i-1,2); 
    end 
     
    if  (k == length(filename)) 
        output = output.'; 
        xlswrite(prevName, output, 'Sheet1'); 
    end 
  
    waitText = strcat(progressText,'% complete... 
(',num2str(k),'/',num2str(numFiles),' files analyzed)'); 
    waitbar(progress,h,waitText) 
    progress = progress + (1 / numFiles * .35); 
    progressText = num2str(progress*100,'%.2f'); 
     



















30% systolic duration counter-pulsation:
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30% systolic duration co-pulsation:  
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30% systolic duration co-pulsation: 
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35% systolic duration counter-pulsation:  
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35% systolic duration counter-pulsation: 
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35% systolic duration co-pulsation: 
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35% systolic duration co-pulsation: 
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40% systolic duration counter-pulsation: 
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40% systolic duration counter-pulsation: 
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40% systolic duration co-pulsation: 
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40% systolic duration co-pulsation: 
